Greater Expectations. Pharmacy based health care: The future for Europe? by Taylor, DG et al.
Greater Expectations
Policy Paper 5
ISBN 978-0-902936-16-4
£15.00
Pharmacy Based Health Care – The Future for Europe?
T
h
e
 S
ch
o
o
l o
f P
h
arm
acy
U
niversity of London
T
h
e
 S
ch
o
o
l o
f P
h
arm
acy
U
niversity of London
Greater Expectations
Pharmacy Based Health Care 
–The Future for Europe?
This report was researched by Dr Sara Garfield, Ms Jean Hawkins,  
Dr Jennifer Newbould, Dr Timothy Rennie and Professor David Taylor 
of The School of Pharmacy, University of London. The quantitative 
survey data presented was commissioned from ICM Research. 
This project was funded by an unconditional educational grant from 
Pfizer Worldwide Pharmaceuticals and managed by Professor Taylor, 
who is accountable for the analysis and conclusions offered. The 
authors thank all those who agreed to be interviewed during the 
course of this study, and have otherwise contributed to it.
© 2007 The School of Pharmacy, University of London
T
h
e
 S
ch
o
o
l o
f P
h
arm
acy
U
niversity of London

Summary and 
Recommendations
Europe’s network of 140,000 community pharmacies provides easy access to medicines to the 
entire population. It should be seen as an important health care asset for the future. 
Primary care doctors and nurses are becoming more involved in treating people with complex 
needs in community settings. Community pharmacists in many parts of Europe are starting to 
provide extended pharmaceutical care services. As more effective medicines become available 
as pharmacy only products, pharmacists will play a more significant part in directly supporting 
self management and improving public health through preventive interventions. 
Factors driving change include population ageing; rising public health expectations and 
health care costs; health service reforms; more transparent pharmacy payment systems; new 
diagnostic and allied tests; the mechanisation of dispensing; and the ongoing development 
of electronic prescribing and patient record systems. 
Wider use of computer based information systems should in time enable pharmacists – with 
appropriate European patient permission – to see and contribute to integrated health records. 
This will help further to facilitate the provision of high quality care and support in community 
pharmacies.
Across six European countries – France, Germany, Greece, Poland, Sweden and the UK – half 
the general population is in favour of extending community pharmacists’ freedom to supply 
people without prescription medicines without patients having to go to a doctor. Particularly 
strong support for this concept was found in Poland and the UK.
Two thirds of the European public believe that community pharmacies should be developed as 
alternatives to doctors’ clinics, to allow people more choice about getting advice and treatment 
for common conditions. There was majority support for this in all of the countries where 
surveys were carried out, with the exception of France. 
French patients have easy access to specialist doctors in the community, and normally 
carry both public and private health insurances. These permit them extensive use of both 
prescription and pharmacy medicines, with low experienced costs. French health and service 
user satisfaction statistics are amongst the best in the world. But the European Commission 
has recently challenged pharmacy ownership rules in both France and Germany. 
In France (as in Greece and Germany) only pharmacists can own pharmacies, and chains are 
not permitted. In Greece there are about 1100 people per community pharmacy, compared 
around 2,500 in France, a little under 4,000 in Poland and Germany, 5,000 in the UK and 
10,000 in Sweden.
Sweden has low prescription medicine distribution costs relative to the size of its market. 
The nationalised pharmacy chain Apoteket has provided relatively good pharmaceutical 
care services. However, the Swedish public’s access to non-prescription medicines has been 
criticised. Plans are presently being drawn up to end Apoteket’s monopoly and to introduce 
a more diverse system. To retain some of the key advantages of the present system, this could 
be based on competing chains of managed pharmacies.
In Germany pioneering attempts have been made by insurance companies to incentivise 
closer working between primary care doctors/general medical practitioners and community 
pharmacists. It is unlikely that public interests can be served efficiently and effectively in the 
absence of good working relationships between community pharmacists and other primary 
care providers. Maintaining and improving standards of collaborative working between medical 
practitioners and community pharmacists should be seen as a key developmental goal.
Poland is characterised by low overall health spending, and high patient payments for 
medicines. The public service mainly supplies generic medicines. Pharmacists in Poland can 
already supply many prescription medicines directly via protocol based arrangements, provided 
the purchaser pays the full cost.
Greece has relatively low medicine prices, and is a key ‘parallel exporter’ of pharmaceuticals to 
other parts of the EU. Greek community pharmacy appears to be highly valued by the public. But 
internally, Greece has not encouraged generic prescribing or given pharmacists powers to substitute 
low cost generics for more expensive brands. The research undertaken revealed fragmented primary 
care arrangements, and claims that questionable payments to doctors are commonplace.
Overall, 71 per cent of the European public interviewed agreed that there is a growing risk 
from counterfeit medicines. This concern should be more effectively addressed than presently 
appears to be the case. Otherwise it will further undermine trust in regulatory authorities, 
pharmacists and the medicines they supply.
Almost 70 per cent of the total European population expressed agreement with the view that 
pharmaceutical companies should be able to communicate directly with the public about 
medicines via regulated websites. As people become more educated and affluent they are 
likely to want freer access to information, and more equal relationships with health care 
professionals. European authorities should review inappropriately paternalistic and outdated 
regulatory approaches. 
The UK has a strong system of clinical pharmacy in hospital settings. The NHS is seeking to 
build on this in the community, in part through options such as independent pharmacist 
prescribing. This may in time open up radical new service delivery opportunities. But in the 
immediate future developing better community pharmaceutical care in contexts such as repeat 
dispensing and the supply by pharmacists (where necessary via protocols) of medicines for 
common conditions are more important priorities. It is in the latter areas that British experience 
is most likely to have pan European relevance.
There are a wide range of opportunities for pharmaceutical companies and community pharmacy 
to work together to extend and improve pharmacy based care. Such partnerships should be 
explicitly aimed the improving public’s health. They may primarily relate to the development 
of ‘disease management’ models that will help to ensure that community pharmacy can play a 
better integrated role in the overall process of health care delivery. But other opportunities exist 
in areas such as enhancing professional education, strengthening European medicines supply 
chain integrity, and strengthening doctor/community pharmacist working partnerships.
Contents
Introduction                                 7
A model for the future?                         8
European public opinion on pharmacy’s 
potential to deliver health care                      9
Complementary data                          12
Pharmacists’ views                             13
Community Pharmacy in the United Kingdom          13
Community Pharmacy in France          17
Community Pharmacy in Germany                 19
Community Pharmacy in Greece          23
Community Pharmacy in Poland                  25
Community Pharmacy in Sweden                  27
Partnerships for better care                        30
Complementary business models?                  30
Conclusion                                  35
References                                  36

Greater Expectations 7
Introduction
Across the European Union a total of some 140,000 
community pharmacies, employing around a million 
pharmacists and other staff, dispense annually 5 billion 
prescription items and supply some 30 billion Euros (£20 
billion) worth of non-prescription pharmacy treatments. They 
provide highly accessible medicines supply and health care 
advice and support services, in both rural and urban areas. 
Europe’s pharmacy network contributes significantly to the 
safety and wellbeing of the public, and to prescribing quality. 
It is provided at an estimated cost (including pharmacy fees 
and product sales margins) of between 0.3 and 0.4 per cent 
of the Union’s GDP.
The scale and value of this achievement, and that of the 
medicines wholesalers and manufacturers that efficiently 
underpin European community pharmacy, deserves 
recognition. As the European population’s medicines related 
needs and health care expectations continue to evolve, the 
community pharmacy base represents an important asset 
for the future. It has the potential to deliver convenient 
and timely access to an increasing range of pharmaceutical 
products and health services designed to keep as many people 
as possible healthy for as long as possible, while also allowing 
pharmaceutical care for established conditions to be delivered 
safely and conveniently (Figure 1). 
An extended provision of pharmacy based care and where 
appropriate pharmacist supported patient self management 
will further free the time of doctors and other primary care 
professionals to deliver relatively complex support for people 
living with difficult health and allied social care problems in 
the community. This should in turn enable hospital stays to be 
minimised and overall health care efficiency and effectiveness 
to be optimised. The ideal endpoint is greater consumer 
independence, coupled with enhanced health outcomes.
Pharmacists have typically acted as agents for health care 
funders.  Their role has in large part been to buy medicines 
as cost effectively as they can and then to supply them 
at approved prices to patients. Across the Union overall 
pharmacy incomes have been derived from dispensing and 
professional service fees, together with the margins taken 
from both reimbursed prescription medicines and other 
goods purchased directly by pharmacy customers (Huttin 
1996). Historically, the latter have been the dominant 
component of the community pharmacists’ financial 
‘incentivisation’, and even today there are parts of Europe 
where community pharmacy is totally reliant on this income 
source.
However, community pharmacists throughout Europe – like 
the pharmaceutical wholesalers supplying them and the 
pharmaceutical companies which discover, develop and make 
medicines – today face a number of challenges that threaten 
their ‘traditional business model’. The forces now promoting 
changes in pharmacy include:
•	 the emergence of managed health services, which 
are in some contexts shifting responsibilities for assuring 
care standards away from health professionals. They are 
also seeking to drive down costs by not only moving care 
provision out of more expensive facilities, but pressing for 
better value for money throughout systems. As both public 
and private sector management capacities develop, so 
pressures have grown to make the earnings of community 
pharmacists more transparent and directly related to 
work done. Similarly, demands to minimise costs through 
supplying lowest possible overall price generic and other 
medicines are becoming progressively more intense. 
While some commentators see this as promoting the 
‘re-professionalisation’ of community pharmacy, many 
pharmacists may feel under increasing threat;
Figure 1. Twenty First Century Community Pharmacy Opportunities
Helping healthy people and individuals with common 
conditions to stay healthy and/or live well
Institutional 
care, 
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social roles
Community care, 
normal social roles
Treating seriously ill patients with complex needs
Community pharmacy based health care
Modernised primary/community 
based medical and nursing care
The traditional focus of 
medical power – hospital care
Pharmaceutical care
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•	 pressures for ‘deregulation’ in areas such as 
pharmacy ownership. Exceptions such as the UK have 
long allowed non-pharmacists to own pharmacies, and for 
chains of pharmacies to be established. But this is atypical. 
In major EU member states such as France the ownership 
of pharmacies remains confined to pharmacists, and 
the formation of chains (as distinct from federations 
of independently owned pharmacies) is prohibited. 
Organisations representing community pharmacists in 
such countries have argued that deregulation would in 
the ownership context undermine professional values 
and autonomy, and replace them with unwanted 
commercialism and managerialism. Norway is sometimes 
quoted as an example of a country where deregulation may 
from a pharmacy perspective have had some undesirable 
consequences (Vogler et al 2006). Yet some policy 
makers and sections of the public tend to see traditional 
community pharmacists as ‘merely shopkeepers’ (Coulter 
and Magee 2003);
•	 the ongoing development of computer systems 
capable of supporting the automation of many 
aspects of medicines dispensing and the electronic 
storage and transmission of not only prescriptions, but 
also medicines information and patient/customer health 
records. For instance, companies such as Medco in the 
United States – which claims to be the world’s most 
advanced pharmacy – operate centralised dispensing 
facilities, and supply made up prescriptions directly to 
patients’ homes and other locations. At the same time 
Medco employs some 700 expert pharmacists, whose roles 
include giving support to medicine users via telephone 
and the internet. Such options are now being actively 
explored in parts of Europe, including both Sweden and 
the UK;
•	 pharmaceutical science and allied technical 
advances, ranging from the introduction of new high 
cost treatments (which are today most likely to benefit 
relatively small numbers of people receiving hospital 
care) and innovative forms of risk factor and diagnostic 
testing.  As the proportion of overall medicines spending 
associated with major therapeutic innovations designed 
for the use in the community declines, so opportunities 
for the provision of older pharmaceutical products in new 
formats, such as pharmacy only medicines, may increase; 
and
•	 the emergence of new consumer requirements, 
and changed health care needs at both the individual and 
the population levels. Europe’s population continues to 
age and – on average, at least – to become better educated 
and more used to affluence, while also more diverse.  As a 
result, expectations of health and health care professionals 
are altering, sometimes in conflicting ways. Required 
standards of medicines and other forms of care safety are 
higher than ever before. Yet many people also want more 
personal autonomy with regard to selecting and accepting 
care, and greater service convenience. This presents new 
opportunities for service provision, alongside pressures 
to ‘modernise’ professional behaviours and concepts of 
professionalism.
The immediate pace of change in pharmacy should not be 
exaggerated. As experiences in fields such as, say, customer 
uptake of ‘over the counter’ (OTC) treatments for raised 
cholesterol levels in the UK (where simvastatin has been 
available as a pharmacy medicine since 2004), the public’s 
behaviour may be slower to alter than is sometimes expected. 
But there can nevertheless be no doubt that European 
pharmacy is facing new circumstances. 
In the context of British pharmacy, the actions being taken 
to respond to the changing environment range from reforms 
intended to strengthen regulation and accountability and 
to further develop pharmacy’s leadership, through to the 
introduction of pharmacist prescribing and the provision by 
NHS community pharmacists of medicines use reviews (MURs 
– see Box 1). It may broadly be said that UK pharmacy is 
– following the successful development of a clinical role in the 
hospital setting – moving to adopt a clinical care and public 
health improvement role in the community. It is also striving 
to retain a pivotal part in the safe supply of prescription and 
OTC medicines, partly through the more flexible use of non-
pharmacy labour and technologies relevant to dispensing.
Box 1. Medicine Use Reviews (MURs)
Pharmacy delivered MURs were introduced as a 
nationally funded part of a new community pharmacy 
contract in England, first implemented in 2004. 
After a relatively slow start, over 14,000 community 
pharmacists have now been accredited to provide 
them. Current figures indicate that in the order of a 
million community pharmacy MURs will be conducted 
in the coming year. 
Broadly defined, medication reviews can involve 
anything from evaluations of patients’ problems in 
medicine taking to much more detailed analyses of 
clinical care strategies and/or the delivery of complex 
behavioural support programmes. The English MUR 
model presently being purchased via PCTs (in Scotland, 
MURs are not directly funded) is aimed at the former 
rather than the latter. This is not always clearly 
understood.
Questions have been raised in relation to the practical 
value of MURs (as they are currently conducted) to 
general medical practitioners and patients. As yet it is 
uncertain how much they are contributing to medicines 
waste reduction and better therapeutic outcomes. 
However, there is evidence that in individual cases they 
are beneficial, and can even be life saving (Newbould 
and Taylor 2007). The introduction of MURs serves as 
a robust demonstration that community pharmacies 
and pharmacists can respond to new incentives, and 
acquire new skill sets.
A model for the future?
Against this background this report reviews the development of 
community pharmacy in five purposively selected EU member 
states – France, Germany, Greece, Poland and Sweden – relative 
to the UK’s experience. Drawing on additional information 
about community pharmacy elsewhere in Europe, it discusses 
the extent to which the British community pharmacy 
‘experiment’ is likely to offer a model for the future which other 
European countries will adopt. It seeks to identify features of 
other pharmaceutical and wider health care systems that the 
UK might beneficially seek to emulate. 
This study also considers the quality of the partnerships 
existing between community pharmacists and other primary 
care professionals such as family doctors and community 
based specialists, and the pharmaceutical companies which 
develop and supply medicines. With regard to this last area 
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the research question addressed was ‘what do community 
pharmacists believe that research based pharmaceutical companies 
could and should do in the future to help them adapt to their 
changing environments?’ 
The first section below describes the findings of quantitative 
research undertaken in the autumn of 2007 into public 
attitudes relating to pharmacy and European medicines 
supply. Following that, the next presents the findings 
of qualitative research undertaken amongst a total of 30 
European pharmacists and pharmacy policy makers during 
the summer and autumn of 2007, together with information 
derived from a structured literature review. 
The final section offers an analysis based on the aggregated 
findings of this study. It considers the future of European 
community pharmacy, and factors which could enable it 
successfully to build on its existing contributions to health 
and wellbeing in order to provide more convenient clinical 
care and better health outcomes in the twenty first century. 
However, before this, two final sets of introductory points 
deserve further emphasis. 
First, community pharmacy cannot adequately be understood 
in isolation from the communities it exists to serve, and the 
funding, regulatory and organisational contexts in which 
it operates. Previous studies have highlighted characteristic 
differences between northern and southern European pharmacy, 
and between the models characteristic of the English speaking 
world as opposed those that typify central and eastern Europe. 
For instance, British pharmacy, like community pharmacy in the 
US and Australia, has throughout its history been less precisely 
defined in terms of its professional responsibilities than have its 
Germanic counterparts. UK community pharmacies typically 
offer what is in some European pharmacists’ eyes a disturbingly 
wide range of non-medical goods and services. By contrast, 
German community pharmacies provide a more extensive 
range of ‘natural’ herbal and homeopathic treatments than that 
usually available British pharmacies. These differing traditions 
are accompanied by a degree of mutual disapproval. 
Commentators such as van Mil and Schulz (2006), in 
their review of pharmaceutical care provision in Europe, 
also contrast the relatively large populations served by 
Scandinavian pharmacies as opposed to the much smaller 
ones served by French/Mediterranean model community 
pharmacies (Figure 2). However, pharmacy practice research 
has not always fully reflected the importance of sociological 
and economic variables defining not only pharmacy’s wider 
environment, but also specific professional attitudes and 
activities. The approach taken in this report seeks to place 
community pharmacy within a wider context.
are motivated simply by ‘commercialism’, rather than by a 
wish to improve health. Yet criticisms of current professional 
arrangements have mainly stemmed from the OECD, the EU 
and national level competition authorities. (See, for example, 
Paterson et al 2003, Hameleers et al 2004). It has in the main 
been action taken at European level which has been the source 
of challenges to the pharmacy ownership regulations currently 
in place in France and Germany. Similarly, it was a judgement 
of the European Court of Justice (Neroth 2005) on the legality 
of Sweden’s nationalised pharmacy monopoly Apoteket which 
led to plans for introducing new forms of competition there.
This is a complex area, which cannot be discussed in detail 
here. But it may be suggested that in sophisticated modern 
economies public interests are best protected by a judicious 
balance of regulatory control and consumer led competition. 
This is especially so in areas such as health care and medicines 
supply, where inappropriate patterns of consumption are 
likely to be harmful and in which service users are often 
unusually dependent on advice from ‘agents’ – the providers 
of the services they are directly or indirectly (though taxes 
or insurance) purchasing. Just as health service users are 
sometimes at risk of over-using treatments, the funders 
and providers of the latter are often at an at least equal and 
opposite ‘moral hazard’ of inadequately caring.
It would be misleading to suggest that it would ever be in the 
public’s interest fully to deregulate a professional field such 
as pharmacy. Pharmaceutical products will always require 
licensing, and pharmacies and pharmacy systems demand 
appropriate levels of quality assurance. Yet as patterns of ill 
health and patient and consumer autonomy change such 
functions will require re-regulation. The aim of this should be 
to permit the most effective, convenient and affordable possible 
public access to information and medicines, and to ensure that 
goals such as ensuring public safety are not being pursued to a 
degree which is in reality undermining public health.
European public opinion on 
pharmacy’s potential to deliver 
health care 
The research reported here was aimed at providing up-to-date 
insight into European public beliefs about the potential of 
community pharmacists to act as medicines prescribers. A 
linked aim was to assess the degree to which there is support 
for the concept of developing community pharmacies as 
alternative places to general practitioners’ surgeries and formal 
clinics for people to obtain advice about, and treatments for, 
common conditions. Following initial piloting in the UK, 
four questions were selected for use in surveys undertaken 
in each of the six EU member states examined during this 
research – France, Germany, Greece, Poland, Sweden and the 
UK. The survey work undertaken was commissioned from 
ICM Research – see Box 2. 
Figure 2. Estimated Population per Pharmacy, 2007
A second introductory point is that the opponents of community 
pharmacy ‘deregulation’ sometimes argue that its advocates 
A total of over six thousand members of the public were asked 
about the extent to which they agreed or disagreed with the 
following test statements:
1. Assuming no extra patient costs, it would be a good thing 
if community pharmacists could prescribe a wide range of 
prescription only medicines without people having to go to a 
doctor.
2. I believe there is a growing risk from counterfeit medicines in 
Europe.
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Box 2 – ICM’s European public opinion 
research
ICM Research was commissioned by the School of 
Pharmacy, University of London, to interview random 
samples of at least 1000 adults in each of the following 
EU member states: France, Germany, Great Britain, 
Greece, Poland and Sweden. Interviews took place 
between August and November 2007. The survey 
in Greece was delayed because of the impact of the 
major fires that took place during the earlier part of 
this period. In all but the case of Poland a telephone 
based methodology was employed. But achieving a 
nationally representative sample of adults in Poland is 
not possible via telephone. For this reason a face to face 
approach was used. Interviews were conducted across 
all regions within each market and the results shown 
have been weighted to the profiles of adults within 
each country.  ICM is a member of the British Polling 
Council and abides by its rules.  Further information 
at www.icmresearch.co.uk
in the case of Poland and waiting times in the case of the UK. 
In the latter instance (as also so in Sweden) respondents were 
also more likely to have had prior exposure to the concept of 
pharmacists adopting an extended clinical role. 
It is of note, however, that the Swedish population appears 
to be the most polarised in this context, with 44 per cent 
expressing strong disagreement with statement 1 (Table 1a). 
The reasons for this apparent division within Sweden are 
uncertain. Amongst the overall sample, men appeared to be 
marginally more likely to favour pharmacist prescribing of 
prescription only medicines than women. People aged over 
65 were significantly less likely to agree with pharmacist POM 
prescribing than members of the working age population.
Turning to statement 4 – ‘community pharmacies should be 
developed as alternatives to doctors’ clinics, so people have more 
choice about getting advice and treatment for common conditions’ 
– the overall level of agreement is significantly higher, at 65 
per cent (Figure 4). Once again British and Polish respondents 
were most likely to agree (at 78 and 75 per cent respectively). 
The French were least likely to agree (at 44 per cent). In 
the case of the German, Swedish and Greek populations 
approaching two thirds of the overall population expressed 
agreement with the idea of developing pharmacies as 
alternative centres for accessing health care and promoting 
public health improvement.– see Table 1b. 
3. In the United States pharmaceutical companies can provide 
information about prescription medicines directly to the public 
through regulated websites: personally, I believe this should be 
permitted in Europe.
4. Community pharmacies should be developed as alternatives 
to doctors’ clinics, so people have more choice about getting 
advice and treatment for common conditions.
Their responses are shown in Figures 3-6 and Tables 1a-d. 
Support for permitting more pharmacist prescribing of 
prescription medicines stood at 49 per cent in the overall 
population of European respondents interviewed. Overall 
20 per cent strongly agreed, and 28 per cent of respondents 
strongly disagreed, with the view that ‘assuming no extra 
patient costs, it would be a good thing if community pharmacists 
could prescribe a wide range of prescription only medicines without 
people having to go to a doctor.’ 
Figure 3. Levels of agreement with the statement 
‘assuming no extra patient costs, it would be a good thing 
if community pharmacists could prescribe a wide range of 
prescription only medicines without people having to go to 
a doctor.’
At the national level only 38 per cent of Germans and Greeks and 
39 per cent of French respondents agreed with this statement, 
as opposed to 47 per cent of Swedes, 66 per cent of Poles and 
68 per cent of British respondents. These disparities may in 
part relate to levels of dissatisfaction with existing primary care 
arrangements.  Barriers to access include factors such as charges 
Figure 4. Levels of agreement with the statement 
‘community pharmacies should be developed as 
alternatives to doctors’ clinics, so people have more 
choice about getting advice and treatment for common 
conditions’
People aged over 65 years appear, despite their relative lack 
of enthusiasm for pharmacist prescribing, to support this 
less radical development almost as strongly as their younger 
contemporaries. The probable implication of this is that 
providing they still have the assurance of doctor led diagnosis 
and prescribing when required, older people are content with 
the idea of obtaining more day to day care via pharmacies.
Figures 5 and 6 illustrate findings relating to the statements 
‘I believe there is a growing risk from counterfeit medicines in 
Europe’ and ‘in the United States pharmaceutical companies can 
provide information about prescription medicines directly to the 
public through regulated websites: personally, I believe this should 
be permitted in Europe.’ Overall, 71 per cent of the Europeans 
interviewed believe that there is a growing risk from counterfeit 
medicines. Notably, 54 per cent of Germans strongly agreed 
with this statement, compared to only 19 per cent of UK 
respondents (Table 1c). This finding may reflect differing levels 
of trust in policing and regulatory agencies, together with 
other factors related to history, geography and the experienced 
freedom of movement across internal Union borders.
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Table 1a. Percentages agreeing and disagreeing with the test statement ‘Assuming no extra patient costs, it would 
be a good thing if community pharmacists could prescribe a wide range of prescription only medicines without people 
having to go to a doctor.’
France
(No = 1005)
Germany
(No = 1007)
Greece 
(No = 1250)
Poland 
(No = 1013)
Sweden
(No = 1005)
UK
(No = 1016)
Total
No = 6296)
Strongly agree 15 15 15 30 19 29 20
Agree
24 23 23 37 29 39 29
Disagree
23 34 28 21 9 18 22
Strongly disagree 37 29 34 13 44 12 28
Table 1b. Percentages agreeing and disagreeing with the test statement ‘Community pharmacies should be developed as 
alternatives to doctors’ clinics, so people have more choice about getting advice and treatment for common conditions.’
France
(No = 1005)
Germany
(No = 1007)
Greece 
(No = 1250)
Poland 
(No = 1013)
Sweden
(No = 1005)
UK
(No = 1016)
Total
No = 6296)
Strongly agree 18 22 26 31 28 34 26
Agree 27 41 36 45 35 44 38
Disagree 20 22 24 18 9 13 18
Strongly disagree 35 14 14 7 28 7 17
Table 1c. Percentages agreeing and disagreeing with the test statement ‘I believe there is a growing risk from counterfeit 
medicines in Europe.’
France
(No = 1005)
Germany
(No = 1007)
Greece 
(No = 1250)
Poland 
(No = 1013)
Sweden
(No = 1005)
UK
(No = 1016)
Total
No = 6296)
Strongly agree 32 53 35 29 37 19 34
Agree 29 33 47 43 46 36 39
Disagree 17 11 14 23 8 18 15
Strongly disagree 20 3 4 6 9 5 8
Table 1d. Percentages agreeing and disagreeing with the test statement ‘In the United States pharmaceutical companies 
can provide information about prescription medicines directly to the public through regulated websites: personally, I believe 
this should be permitted in Europe.’
France
(No = 1005)
Germany
(No = 1007)
Greece 
(No = 1250)
Poland 
(No = 1013)
Sweden
(No = 1005)
UK
(No = 1016)
Total
No = 6296)
Strongly agree 28 25 34 35 33 26 30
Agree 36 39 34 47 31 41 38
Disagree 15 22 18 14 7 16 16
Strongly disagree 21 14 13 4 28 12 15
Finally, 68 per cent of the total population agreed with the 
statement suggesting that Europe should permit pharmaceutical 
companies to communicate directly with potential customers 
via their websites. In Poland just over 80 per cent of the 
population surveyed supported this view, while only 4 per 
cent strongly disagreed with it (Table 1d). The country with the 
highest rate of strongly expressed disagreement is once again 
Sweden, with 28 per cent strongly opposing the proposition 
that pharmaceutical companies should be allowed more 
freedom to communicate directly with the public.
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As with pharmacy prescribing, older people are less likely 
to approve of pharmaceutical companies being empowered 
to provide information about their products directly to the 
public than younger persons. On average, 73 per cent of the 
total population aged under 55 years favoured obtaining 
access to pharmaceutical company websites, with almost 
half of this group indicating that they strongly support such 
progress. Yet in the population aged over the 55 year threshold 
the proportion supporting European access to (regulated) 
pharmaceutical company information was in aggregate just 
under 60 per cent. This observed variance may in part be 
accounted for by age related differences in computer literacy 
rates, rather than variations in attitudes related to personal 
rights to information access.
based advice and support. But it can be confidently concluded 
that the British and Polish populations are already very open 
to the idea that pharmacists should play an extended role 
in providing health care, and that this direction of future 
progress is, with the possible exception of France, generally 
favoured in all the nations surveyed.
As already indicated, the reasons why the UK and Poland 
seem to be especially in favour of extending pharmacists’ 
roles may differ significantly. In Britain, for instance, there has 
been an extensive policy debate dating back to the 1980s, and 
the publication of reports such as the Nuffield Foundation’s 
Pharmacy (Nuffield Foundation, 1986). This highlighted the 
potential benefits of professional change. Poland had yet 
to emerge from communist control in the 1980s, and even 
today health care provision there remains in a number of 
important respects unsatisfactory. Many Polish people have 
relatively limited access to newer medicines, and are more 
concerned about costs as a barrier to health care access than 
most of their peers elsewhere in the EU. Further, as described 
later in this report, a proportion is already used to purchasing 
prescription medicines directly from pharmacists working on 
a protocol basis.
Research published by the Picker Institute (Coulter and Magee 
2003) offers further insight. For example, Figures 7 and 8 show 
that UK doctors were (when this investigation was undertaken 
in 2000/01) rated higher than others in Europe with regard to 
factors like listening to patients and explaining treatments. 
Yet both Polish and British patients were unusually dissatisfied 
with the choices available to them within their health care 
systems. 
The Picker Institute in addition found that in countries such 
as Germany pharmacists are widely regarded as excellent 
information providers, and seen as providing an important 
safety check. There are some concerns about pharmacists 
being ‘shopkeepers’ influenced by commercial rather 
than professional incentives. Nevertheless, the belief that 
pharmacists should offer an independent check on prescribing 
safety could well, perhaps paradoxically, be one of the main 
reasons why a proportion of Europeans are as yet unwilling to 
accept that they should more frequently act as independent 
health care practitioners. Magee and Coulter concluded that 
‘European patients tend to react conservatively to suggestions that 
professional roles might change, but they readily adapt to these 
changes when they occur.’ 
In conclusion, the quantitative research findings presented 
above support the view that an increasing proportion of 
Europeans want pharmacists and pharmacies to play a more 
central role in health care provision. Given appropriate 
leadership, and informed support from other health care 
providers, community pharmacy is well placed to offer people 
innovative forms of pharmaceutical care as the twenty first 
century progresses. 
The most significant opportunities for this presently seem to 
relate to meeting the needs of working age people who are 
seeking wider choice in, or easier access to, health care, and 
to tests and treatments in contexts where the perceived risk of 
iatrogenic illness is relatively low. But as new generations of 
older people with better health and a greater desire for personal 
autonomy emerge, they too may develop raised expectations 
of what can and should be delivered via pharmacy. The latter 
may increasingly offer clinical care alongside medicines 
supply, information and support for prescribing doctors and 
other professionals seeking to optimise medicinal therapy.
Figure 5. Levels of agreement with the statement ‘I 
believe there is a growing risk from counterfeit medicines 
in Europe’
Figure 6. Levels of agreement with the statement ‘in 
the United States pharmaceutical companies can provide 
information about prescription medicines directly to the 
public through regulated websites: personally, I believe 
this should be permitted in Europe.’
Complementary data
These findings could be taken to question the public 
acceptability of some aspects of current EU wide policy on 
controlling public exposures to pharmaceutical care related 
information which might influence treatment demand, 
or challenge aspects of traditional authority. It would 
require further research to explain why, for instance, the 
Swedish community (which may amongst certain sections 
of its population have a particularly ‘collectivist’ culture) 
contains a significant minority who are strongly opposed to 
both pharmacist prescribing of prescription medicines and 
enhanced public access to pharmaceutical company website 
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Figure 7. Responses to the question ‘how often did the 
doctor involve you as much as you wanted in decisions 
about your care?’
Source: Coulter and Magee 2003
Figure 8. Proportions of adult communities rating 
opportunities for health care choice as good or very 
good in selected European countries.
Source: Coulter and Magee 2003
Pharmacists’ views 
The findings of a qualitative survey of 30 European 
pharmacists and pharmacy policy makers conducted during 
the Summer and Autumn of 2007 are reported below. This 
research was supported by a structured literature review, 
aimed primarily at identifying recently reported pharmacy 
practice developments in the five selected comparator 
countries – France, Germany, Greece, Poland and Sweden. An 
overview of UK developments is presented first. This offers an 
outline against which the views expressed and developments 
described by pharmacists working in other European settings 
can be considered. During the analytical process a large 
number of specific topics were identified. But for the purposes 
of this report the research findings and observations made 
are presented under five thematic headings:
1. The health care context in which community 
pharmacy services are provided. (This includes 
topics such as health service funding, and patterns of 
primary care provision.)
2. Structural and regulatory dimensions of 
community pharmacy. (Payment systems, numbers 
of community pharmacies, ownership regulations, 
e-pharmacy developments etc.)
3. Pharmacy practice and patient care developments. 
(Including pharmacy prescribing of OTC and other 
medicines, the provision of health promotion and advice, 
the development of electronic care records and the impact 
of new dispensing technologies.)
4. Pharmaceutical cost controls. (Pharmaceutical price 
and spending controls, regulation of marketing and allied 
activities)
5. Future opportunities. (Including professional 
leadership issues; likely directions of professional role 
change; educational, professional and industry partnership 
opportunities.)
Community Pharmacy in the United 
Kingdom
The health care context
The United Kingdom is divided into four devolved 
administrations – England (covering approaching 90 per 
cent of the population of 60 million), Scotland, Wales and 
Northern Ireland. NHS structures and funding levels vary 
between the UK nations. But for the purposes of this report 
the remarks offered here will refer to the NHS in England, 
unless otherwise stated.
Following mounting concern about NHS funding limitations 
in the 1990s, public spending on health rose risen rapidly in 
the UK. In 2006 it accounted for 9.4 per cent of GDP. NHS 
spending was the main element of this total, at 8.2 per cent 
of GDP (OHE 2007). The NHS is the largest single health care 
organisation in Europe, employing well over one million 
people. However, the number of doctors employed and 
hospital beds provided is significantly below the equivalent 
figures for countries such as Germany and France. The 
limited availability of medical manpower may be one of the 
variables underpinning British efforts to extend community 
pharmacists’ roles.
The NHS is (notwithstanding the existence of a nominal 
national insurance scheme) funded by central taxation. 
Services are purchased/commissioned from providers via (in 
England) Primary Care Trusts. PCTs are via the Strategic Health 
Authorities ultimately accountable to central government. 
They typically serve geographically defined populations of 
about 300,000. Despite some popular confusion about the 
significance of national insurance payments, the NHS is not 
an insurance system: there is no defined set of individual 
service entitlements. It was created in the late 1940s as a 
universally available service for the equitable delivery of 
(implicitly rationed) health care in relation to need. PCTs still 
often place emphasis on their duty to reduce inequalities in 
health, as distinct from optimising service user satisfaction.
A little over 10 per cent of the UK population also has private 
health insurance. Social care provision in England is means 
tested, although arrangements in Scotland and Northern 
Ireland differ. In England there have been recurrent tensions 
regarding what elements of care and support for older and 
other people with long term conditions such as dementia(s) 
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should be provided ‘free’ by the NHS or charged for, because 
they are provided via local government funded social 
services.
Most of the institutional providers of health care used by NHS 
PCTs remain publicly owned. However, newly established 
NHS ‘Foundation Trusts’ have a relatively high degree of 
independence. Within the traditional NHS culture there is 
often antagonism towards private sector service providers, and 
permitting additional ‘top up’ personal payments for services 
not regarded as adequately cost effective for mass provision. 
Primary care doctors (general medical practitioners - GPs) 
and community pharmacists are contracted to the NHS at 
the individual practice and (independent or chain) pharmacy 
levels. Community pharmacists are regarded as working in 
the private sector, while GPs are more widely seen as integral 
to the NHS. It is not normally possible for NHS (or private) 
service users to access specialist care in the UK without referral 
by a primary care doctor/GP. Patients must be registered with 
their GP practices, but may choose any community pharmacy. 
General practitioner control of the gateway to secondary care 
provision is often regarded as significant strength in care 
management terms. But at a political level it has been criticised. 
It is on occasions seen as a cause rather than a reflection of 
restricted consumer choice within the NHS system.
Important changes to the national community pharmacy and 
GP contracts were made in 2004. The GP contract contains a 
Quality and Outcomes Framework (QOF), which means that 
a large element of practice income is dependent on being 
able to show evidence of good practice. Despite attempts to 
make community pharmacy incomes more transparent, and 
the introduction of three different levels of national and 
local payment in the 2004 community pharmacy contract, 
no provision equivalent to the QOF exists to promote 
pharmaceutical care development (APPG 2007). There are also 
no contractually based mechanisms for incentivising GPs and 
community pharmacists to work together in a complementary 
fashion. Levels of GP/pharmacy collaboration in the UK were 
described by one well placed respondent as ‘variable, and down 
to personality and luck as much as anything else.’ 
PCTs are not generally regarded by pharmacists (or other 
observers) as having prioritised a robust and comprehensive 
strategic approach to community pharmacy service 
commissioning. However, significant progress has been made 
in areas such as smoking cessation support (Brock et al 2007) 
and the employment of pharmacist prescribing advisors and 
allied staff in PCTs. These last are increasingly involved in 
promoting community pharmacy service developments. (See 
also Silcock et al 2004, Noyce 2007, Newbould and Taylor 
2007.)
Structural and regulatory dimensions
Community pharmacy incomes in the UK remain largely 
dependent on NHS fees linked to dispensing volumes, coupled 
with the profit margins obtained from medicines supplied to 
NHS patients and OTC users. Community pharmacists in the 
UK are incentivised to obtain the largest discounts they can 
on medicines supplied to NHS users via an earnings claw-back 
scheme, the closest equivalent to which elsewhere in the EU 
exists in Holland. This has helped to make the UK (along with 
Germany) one of the two largest importers of parallel traded 
(patented) medicines in Europe.
Additional NHS community pharmacy fees have recently 
been introduced (in England and Wales) for conducting 
Medicine Use Reviews, and for local services aimed at public 
health improvement. But these are not as yet a major source 
of income. In the Autumn of 2007 the reimbursement price 
levels for generic medicines were cut, and some professional 
fees were also reduced because community pharmacy NHS 
related profits had risen above target levels. This action can 
be linked to a more general European trend towards making 
pharmacy incomes more transparent, and less dependent 
on factors such as high discounts on generic and branded 
medicines. (Pharmacists said that generic medicine margins 
are often in the order of 100 per cent.)
In the UK (and the Republic of Ireland, where medicines 
wholesaling/distribution margins were cut sharply in the 
Autumn of 2007) anyone can own any number of pharmacies, 
and there are no restrictions on the opening of new ones. Yet 
to obtain an NHS contract in England an application must be 
made to the local PCT. Despite some regulatory relaxation in 
2005, the latter normally has the power not to grant a contract 
if it is felt that a new pharmacy is not locally required. 
There are in the order of 12,000 community pharmacies in 
the UK, each on average serving some 5,000 people. The total 
number of active (full and part time) community pharmacists 
is approaching 30,000, and the total additional workforce 
employed in UK community pharmacies is in the order of 
80,000 (Patel 2007). These include both counter assistants 
and dispensing technicians: the latter are now registered 
and gaining increased dispensing responsibilities. There 
are considerable variations in the number of prescriptions 
dispensed by smaller as opposed to larger pharmacies. The 20 
per cent of smallest volume pharmacies in Britain dispense 
2,000 or less NHS prescription items per month, at which level 
their financial viability may be challenged. The largest 20 per 
cent of pharmacies (which are more often owned by chains, 
and are typically found in ‘high footfall’ locations) dispense 
10,000 or more prescription items per month.  
Internet sales of medicines are permitted in the UK. Legally, 
prescription and pharmacy products should only be supplied 
via registered pharmacies and with an appropriate medical 
prescription. In the context of over-the-counter medicines 
supply, the UK operates a three level licensing system of 
Prescription Only (POM), Pharmacy (P) and General Sales 
List (GSL) medicines, with the latter being available from 
any retail outlet. This again makes the UK different from 
much of the rest of Europe, where almost all medicines are 
supplied via pharmacies. OTC medicines in the UK account 
in total (including NHS funded supply) for 16 per cent of 
all community pharmacy medicines sales by value. Self 
purchased OTC medicines represent 12 per cent of the UK 
medicines market outside hospitals (AESGP 2007).
It is relevant to note that Holland (where patients are registered 
with pharmacies, and pharmacists are more clinically focussed 
than in many other countries – Box 3) provides an example 
of another exception to the more common rule, that 
medicines are normally only available via pharmacies. In The 
Netherlands separately located druggists have traditionally 
supplied over-the-counter products, although recent reforms 
are changing this arrangement. 
It is also important to record that in the US there is presently 
no P medicines category. This underlies some significant 
prescribing and medicine pricing variations between America 
and Europe. A British pharmacist with an interest in this area 
commented ‘they (US authorities) are beginning to wake up to 
what they are missing by not having pharmacy only medicines – the 
FDA has recently made some proposals. It has all been rather slow 
(with respect to recent PoM to P classification switches in the 
UK) but if the Americans come in it could really drive it.’
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Box 3. Pharmacy in The Netherlands
Pharmacists in Holland have traditionally had six years 
of pre-qualification training and education, to a level 
of expertise comparable to – and in some ways superior 
to – that of medical graduates. Despite relatively 
high levels of GP dispensing in Holland, pharmacists 
there play an important role in setting and assuring 
therapeutic standards in community settings. They 
are also empowered to make generic substitutions 
for branded medicines, when this is not specifically 
prevented by the prescribing doctor. Key characteristics 
of Dutch community pharmacy include:
•	 high levels of ‘extemporaneous’ dispensing 
– around 6 per cent of all prescribed medicines are 
made in the pharmacy;
•	 high populations served per pharmacy. There 
are about 8,000 people per pharmacy in The 
Netherlands, compared with 5,000 in the UK and 
about 2,500 in France; and
•	 an extensive use of qualified technicians in 
dispensing and allied roles, leaving pharmacists 
free to contribute to clinical care. 
There are few large primary care medical practices in 
Holland – there are still significant numbers of single 
handed primary care doctors. Recent Dutch reforms 
have permitted the ownership of pharmacies by non-
pharmacists and corporate bodies. Other regulatory 
changes have also served to reduce the discount levels 
pharmacists are able to enjoy on medicine purchases. 
Such developments suggest that pharmacists in 
Holland must, like their professional peers elsewhere 
in the Union, continue to extend their roles in ways 
that add increased value to medicines taking, and serve 
cost effectively to improve the public’s health.
led process for supplying and monitoring patients with 
long term conditions, which may also effectively reduce 
medicines wastage;
•	 Patient  Group Direct ions  (PGDs)  and 
supplementary pharmacist prescribing. These are 
variants of protocol prescribing (Emmerton et al 2004), 
which (like the practice of clinical pharmacy in ward and 
other hospital settings) is relatively advanced in the UK 
as opposed to most other parts of Europe. In essence both 
permit pharmacists to provide POM medicines directly to 
patients within frameworks agreed locally with doctors;
•	 independent pharmacist prescribing (IPP). This 
involves community pharmacists acting – as do already 
some community based nurses in the UK – as autonomous 
health care practitioners, capable of diagnosing conditions 
and authorising patient access to prescription drugs. 
Independent prescribers work in parallel with, rather than 
under the supervision of, the medical profession. IPP is 
therefore a potentially important innovation, although 
as yet it has not been introduced on a significant scale;
•	 extended provision for technician dispensing in 
the community context. This has been a controversial 
area, and in certain respects Britain has lagged behind EU 
states such as Holland and Sweden in respect to permitting 
non-pharmacists to take on increased responsibilities for 
dispensing within pharmacist managed systems. However, 
there is now progress in this direction;
•	 electronic prescribing, and the electronic 
transmission of prescriptions (ETP) and, in future, 
patient’s electronic care records from doctors’ surgeries 
to community pharmacies or large scale ‘dispensing 
warehouses’. The UK primary care system is already 
highly computerised, compared to primary care medicine 
in countries such as the United States and Germany 
(The Commonwealth Fund/Health Affairs 2006). The 
NHS is now midway through a major centrally directed 
information technology programme. This will eventually 
link all hospitals, medical practices and other NHS 
facilities in order to allow the instant transmission of 
patient records and test results of all types, and provide 
a better inpatient care booking system. ETP is already 
partially in place, although the extent to which and terms 
upon which community pharmacists will have access to 
patient care records remains uncertain; and 
•	 other developments relevant to the further 
development of pharmacist provided health 
care in the community. These include ‘minor 
ailments’ schemes (designed to allow pharmacists to 
relieve GP workloads without imposing additional costs 
on service users); CVD risk factor, diabetes, Chlamydia 
and other screening programmes; emergency hormonal 
contraception supply programmes; services for drug 
misusers, including supervised methadone supply and 
needle exchanges; smoking cessation support; and out-
of-hours care services. 
The latter provisions are almost all locally funded, on a 
highly variable basis. But for the purposes of this summary 
description the point to stress is that they are becoming more 
widely available. NHS policy on community pharmacy is 
aimed at developing what has sometimes been regarded as 
‘an under-used resource’ into a more clinically oriented ‘front 
line’ primary/public health care provider (see, for instance, A 
Vision for Pharmacy in the New NHS – DoH 2003 – and Choosing 
Health through Pharmacy – a Programme for Pharmaceutical 
Pharmacy practice developments
The established tasks of community pharmacists in the UK 
centre, as in the rest of Europe, on supplying medicines safely 
to the public. This is in part done by identifying possible 
contra-indications and correcting medical prescribing errors. 
Pharmacists also have a generally accepted diagnostic and 
therapeutic role in the context of recommending over-the-
counter medicines and other non-prescription treatments, 
and supporting self care. 
The perceived social status of community pharmacists in the 
British social and health care environment is below that of 
GPs. This can create communication difficulties. But most 
pharmacists say that they are normally able to communicate 
concerns about patient safety and wellbeing effectively to 
doctors. 
With regard to extending pharmacists’ health care roles, it 
has been officially recognised (as it has in other EU countries) 
that one major way forward lies in extending the range of P 
medicines available. However, additional NHS community 
pharmacy practice innovations promoted during the past 
decade include:
•	 new repeat dispensing arrangements. The initial 
impact of the changes made in this area was limited. 
But they are leading to a more convenient pharmacy 
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2007). The voluntary acceptance by British doctors of generic 
prescribing (and frequently molecular substitution, when 
significant savings can be made) explains why the UK has 
not moved to permit generic or other forms of substitution 
by community pharmacists. 
The high use of pharmaceutical parallel imports from European 
countries with lower officially defined medicine prices has in 
part been facilitated by a highly concentrated and professional 
wholesaling system. (Wholesaling companies can own 
pharmacies, and have arguably become increasingly dominant 
‘players’ in the pharmaceutical sector.) This is supplemented 
by the activities of smaller licensed traders. A proportion of 
community pharmacies are also licensed parallel traders.
British pharmaceutical price and cost controls are in part 
supplemented by prescription charges. About 80 per cent of 
NHS prescriptions issued are exempt from charges because of 
factors such as patients’ ages. But for the remainder a flat rate 
charge of around 10 Euros per item is applied, and collected 
via community pharmacies. In instances where the cost of the 
medicine concerned is below that of the charge patients can 
elect to purchase privately, if in the case of POMs a private 
prescription can be obtained.
The impact of the PPRS has also been augmented since 
the end of the 1990s by the creation of NICE (now the 
National Institute for Health and Clinical Excellence) and 
similar bodies. NICE is an NHS agency that conducts health 
economics based analyses, and makes recommendations as 
to whether given products supplied at given (PPRS permitted) 
prices should be regarded as cost effective by NHS purchasers 
and providers. Its recommendations are not legally binding. 
But NICE judgements may effectively block the introduction 
of, or stop NHS prescribing of, products not thought to offer 
sufficient ‘value for money’.
Future opportunities
Alongside the changes outlined above, the UK government 
has (in part because of recent scandals involving poor 
professional practices and in one unique case – the ‘Shipman 
murders’ – large scale crime) introduced a series of reforms 
aimed at changing the powers of health sector professional 
bodies. Observed against the background of new forms of 
consumer representation in the English NHS, these may be 
seen as consistent with other reforms aimed at creating a more 
robustly managed, centrally directed yet locally responsive, 
national health care system.
In the case of pharmacy, proposed changes have included 
creating a new General Pharmaceutical Council to undertake 
regulatory and disciplinary functions outside the ambit of 
the established professional body, the Royal Pharmaceutical 
Society of Great Britain. There has also been controversy 
about the future of the latter body, with some state 
linked and independent interests calling for a movement 
away from ‘sectional representation’ towards ‘altruistic 
professionalism’. 
Such developments have added an extra dimension to the 
UK policy debate about the future of pharmacy. To the extent 
community pharmacy in England is leading European change, 
this is in large part because NHS and related government 
authorities are trying to establish new patterns of practice. 
This positive external pressure may overcome barriers to 
change based on understandable professional fears.
The relationship between community pharmacies and 
pharmaceutical companies has traditionally been based on 
Figure 9. Spending on Prescription and OTC Medicines 
at Manufacturers’ Prices, expressed as a percentage of 
GDP, circa 2004
Source: OHE 2007
Pharmaceutical cost controls
In manufacturers’ price terms, total UK spending on medicines 
(including OTC products) stands at 1.2 per cent of the GDP 
(OHE 2007). This is low in European terms (Figure 9). About 
12 per cent of NHS outlays are accounted for by community 
pharmacy costs, including medicine purchases and professional 
fees. This proportion has fallen in recent years.
All EU member states have different approaches to 
controlling pharmaceutical prices and spending. In the UK 
the Pharmaceutical Price Regulation Scheme (PPRS), which 
is internationally unique, limits pharmaceutical company 
profits on medicines supplied to NHS to given ceilings, after 
allowable research, marketing and other costs have been 
deducted. It has effectively allowed for free pricing of new 
products, partly balanced by downward price pressures on 
companies’ other products. 
The official prices of patented pharmaceuticals in the UK have 
often been higher than the European average level. But this 
has been accompanied by high levels of parallel importing, 
low rates of new product prescribing and high (80 per cent 
plus) levels of generic prescribing by family doctors (OFT 
Public Health – DoH 2005). UK pharmacists interviewed for the 
purposes of this research recognised and in the main approved 
of this direction of travel. Nevertheless, some respondents also 
expressed concerns about the continuing financial viability 
of community pharmacy, were its main income base to shift 
away from medicines supply. They also questioned the ability 
of a proportion of the profession to take on a significantly 
extended health care role without further investment in 
education and training.
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shared business and health values. Some pharmacists (in the 
UK and elsewhere) say that they see regulations surrounding 
areas like pharmacy ownership and prescription (as opposed 
to OTC) medicines advertising restrictions as having been 
put in place to prevent pharmaceutical companies from 
undermining their professionalism. But there are examples 
of disease management and allied initiatives funded by the 
pharmaceutical industry that have successfully involved 
pharmacists, and contributed to the development of their 
clinical skills. British pharmacy respondents identified this 
area as a possible way forward for companies seeking to build 
new links with community pharmacy.
Community Pharmacy in France
The health care context
The French health care system was recently named by the 
World Health Organisation as the best in the world in terms 
of access to and choice of specialists for patients, clinical 
quality and public satisfaction. There is notably rapid access 
to specialist care. Total health spending in France stands at 
about 11 per cent of GDP (OECD 2007), of which 80 per 
cent is accounted for by public expenditure. (The equivalent 
figures for Sweden and the UK are closer to 90 per cent. In 
Germany the public share of health spending is roughly 
the same as that in France, while in Poland it is 70 per cent. 
In Greece little more that 40 per cent of health outlays are 
classified as public spending.) 
Like the UK, France has a total population of about 60 
million. Average life expectancy for women is the longest 
in the EU, at 84 years. The French National Health 
Insurance system (NHI) was first established in the 1930s, 
and now (notwithstanding the recent removal of funding 
for unemployed non-nationals of working age) covers all 
French residents. Revenue is primarily raised via compulsory 
employment linked contributions, levied on both employers 
and employees. The approach to health care adopted by 
policy makers in France can be seen as bridging the divide 
between the British (universally available and equitable, but 
also centrally managed and arguably too tightly rationed) 
NHS and the American (liberal and individual choice focused, 
but also costly and inequitable) health system (Rodwin and 
le Pen 2004). 
Over the past 20-30 years various reforms have been 
introduced to enhance cost control. For instance, a family 
doctor system similar to that in the UK has been encouraged, 
although pharmacists interviewed during this research said 
that there are shortages of medical practitioners in some 
areas. It is also of note that in the order of a quarter of all 
French physicians do not accept NHI reimbursement levels 
as payment in full. Important elements of the health care 
insurance system in France include:
•	 the maintenance of citizens’ rights to access the health 
care provider of their choice. French patients can elect to 
bypass primary care and see a specialist directly, although 
this entails lower reimbursement rates. Within primary 
care individuals are not restricted to having to register 
with a single practice/practitioner; and
•	 the use of ‘Mutuelles’ – private coinsurance schemes 
– to complement NHI coverage. These typically  cover 
additional charges, and have had the important effect 
of keeping total out-of-pocket French health care 
expenditures down to (proportionately) one of the 
lowest relative levels recorded anywhere in the OECD 
(see Figure 10). This is one of the factors that explains the 
relatively high levels of prescription and OTC medicines 
use recorded in France. While critics argue that the 
combined effect of French medicines reimbursement 
and co-insurance arrangements has undermined the 
willingness of French people to take responsibility for 
their own care and encouraged the excessive use of (often 
low cost) medicines of questionable value, the system’s 
performance appears to be relatively robust.
Several pharmacists interviewed for this survey said that 
there are high levels of public satisfaction with community 
pharmacy services as they are currently provided. One 
individual with robust knowledge of the French Ordre 
National des Pharmaciens (ONP) commented ‘people do not 
want a change – the pharmacy is a central part of their local 
community.’ Another pharmacist said ‘the new government 
may support it (reform to pharmacy ownership regulations), 
I can see that. But they will have a lot of resistance. We have 
written to the European Commission to say we do not accept 
this.’ Respondents also expressed strong support for a clear 
separation between the role of the doctor and pharmacist 
while also saying that closer communication between 
Figure 10. Out of Pocket and Private Health Insurance 
Spending as a Percentage of Total Health Outlays, 
OECD countries 2005
Source: OECD 2007
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such professionals would be desirable. One suggested that 
there might in future desirably be a trend towards fewer 
larger pharmacies. These could employ a similar number of 
community pharmacists to support more effectively medical 
prescribers and patients.
technicians (préparateurs en pharmacie) can dispense under 
the supervision of a pharmacist. Compared with the total of 
some 55,000 community pharmacists working in France, there 
are approaching 30,000 préparateurs (who are often pharmacy 
students in their third undergraduate year) and an additional 
25,000 pharmacy assistants, who have diplomas but are not 
fully qualified pharmacists.
Pharmacy practice developments
Researchers have remarked that it is relatively difficult for 
other Europeans to access French literature on pharmaceutical 
care and allied developments (van Mil and Schulz 2006). 
Nevertheless, there is evidence that in addition to work in 
areas such as promoting prescribing safety, the development 
of generic substitution (see, for instance Allenet and Barry 
2003) and the provision of smoking cessation and emergency 
hormonal contraception (EHC), French community 
pharmacists are also active in fields such as blood pressure 
measurement (but not its direct treatment). In relation to 
EHC, for instance, it appears that French women look to 
pharmacists to be highly professional sources of expert advice, 
albeit that they may on occasions feel they are treated in an 
inappropriately judgemental manner (Gainer et al 2003).
One respondent with experience of community pharmacy 
practice in several European countries suggested that French 
pharmacists tend to use their professional judgement more 
flexibly than do their German or British peers in situations 
where, for instance, they know a customer has previously 
received a given prescription item.  French pharmacists are also 
often more closely involved in providing laboratory testing 
and analytical services than is so in other Union countries. 
Yet the information gained from interviewees contributing to 
this study suggested that some French pharmacists feel unable 
to move their clinical practice role(s) forward as pro-actively 
as they would wish. One said ‘we organise pilot schemes, but 
they do not lead to permanent services.’ 
A commonly quoted reason for this situation was the belief 
that French doctors (who were described as a ‘very powerful 
lobby’) see the further development of clinical pharmacy in the 
community as a threat to their position, and are often hostile 
to it. A second is that the French public is satisfied with the 
current situation, and might see an extension of pharmacists’ 
professional activities as unwelcome (see previous section). 
At worst, extending pharmacists’ roles may be perceived as 
a threat to the established system in which doctors diagnose 
and prescribe, and in which medicines can in most instances 
be freely obtained. 
Respondents said that they were unaware of developments 
in fields such as the electronic transmission of prescriptions 
or robotic dispensing in France, and did not believe that 
developments in these areas would drive changes in 
community pharmacy in the foreseeable future. Comments 
made on pharmaceutical wholesaling suggested that 
although as in the rest of western Europe this sector of the 
economy has become relatively concentrated in France, it 
still tends to be seen as part of pharmacy’s essentially internal 
support infrastructure. That is, community pharmacy based 
respondents still see themselves as in spirit the ‘owners’ of 
wholesaling enterprises, rather than the reverse.
Respondents also described the development of two forms 
of electronic patient record ‘smart card’, one for informing 
health professionals and the other for identifying individuals 
for co-payment and allied purposes. The former (to date) 
only holds a four month patient medication record. This 
Pharmacists also said that the example offered by the 
development of clinical pharmacy in UK hospitals is of interest. 
Clinical pharmacy is not as yet as extensively developed 
in hospital settings in France. None of the pharmacists 
interviewed suggested that innovations similar to the UK’s 
supplementary and independent pharmacy prescribing 
plans are being considered. Most said that the latter would 
be unlikely to be judged desirable, although one respondent 
questioned the extent to which French community pharmacy 
presently serves to maintain prescribing standards and to 
deliver high quality pharmaceutical care. 
Interviewees’ responses indicated a relatively high degree of 
satisfaction with the social standing and professional role 
of pharmacy. There is a strong cultural emphasis on social 
solidarity in France. Yet private practitioner status appears 
to be positively accepted, and there also seems to be a 
corresponding respect for the freedom of individual service 
users to access care consistent with their personal preferences. 
Even if this involves paying additional fees this last was not 
opposed by French respondents on equity grounds, as may 
more often (ostensibly, at least) be the case in the UK.
Structural and regulatory dimensions
Over 90 per cent of all community pharmacy income in 
France is derived from the provision of reimbursed medicines. 
In the past, community pharmacists have been financially 
rewarded for providing relatively expensive versions of off 
patent medicines. But the system now in place supports the 
provision of lower cost alternatives. From 2000 community 
pharmacists in France have been able to substitute generic 
for branded (off patent) products, and in 2006 the prices of 
generic medicines were significantly reduced. Until the last 
few years generic as opposed to branded medicines accounted 
for only a few per cent of the total volume of medicines 
dispensed. However, this proportion is now rising (Kanavos 
and Taylor 2007). European Generic Medicines Association 
(EGA) data indicate that in 2006 generic products accounted 
for 17 per cent of the French pharmaceutical market by 
volume.
There are approaching 23,000 community pharmacies in 
France, each one on average serving a population of almost 
2,500 people. Pharmacies can only be owned by pharmacists, 
or companies established by pharmacist partners. No owner 
may legally possess more than one pharmacy – chains 
cannot be formed. However, independent pharmacies can 
join together to form consortiums for purchasing and similar 
purposes, and independent pharmacies can in appropriate 
circumstances be located within, for instance, supermarkets 
if they pay rent. There is legislation that determines when a 
new pharmacy can enter the market, based on demographic 
and geographic criteria. These provisions are administered 
by the Prefectures. 
Both prescription and non-prescription medicines can only 
be sold in pharmacies. Internet pharmacy has not been 
developed in France – the selling of medicines via this route 
by community pharmacies has not been permitted. (One 
respondent suggested that people who want to purchase from 
internet sites are, given the comprehensiveness of the French 
system, mainly wanting drugs for illegal purposes.) Only 
pharmacists can dispense independently, although pharmacy 
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– respondents said – is useful for dispensing purposes. But 
it cannot support the delivery of more advanced forms of 
pharmaceutical care. Pharmacists in France do not appear to 
believe that the goal of making fully comprehensive health 
records available is likely to be achieved rapidly. Problems 
relating to the fragmentation of hospital and independent 
physician records were mentioned in this context. It was 
said that many doctors in France have not yet computerised 
their record systems.
Pharmaceutical cost controls
France has one of the highest per capita medicines 
expenditures in the world. In manufacturers’ price terms it 
stands at about 2 per cent of the GDP. The reasons for this 
relate in part to an historical approach which combined 
relatively low (in international terms) unit medicine prices 
for patented medicines with relatively high expenditures 
on off patent branded treatments, and in part to high levels 
of consumption associated with the comprehensiveness of 
French national and private health insurance coverage. 
Although France has one of the largest non-prescription 
medicine markets in Europe (accounting for 20 per cent of 
total pharmaceutical outlays in the community setting) it 
has proportionately the lowest level of out-of-pocket OTC 
spending (AESGP 2007). 
The current French pharmaceutical pricing approach sets 
NHI reimbursement levels (which define the overall price 
a medicine can be sold at) for medicines via the Comité 
Economique des Produits de Santé (CEPS). This employs 
a range of health economics based and other criteria in 
calculating reimbursement levels, and promises (conditional) 
free pricing for innovations with a high health gain potential. 
(Medicines that are not reimbursable under the NHI scheme 
are also priced freely.) Consumers can be charged up to 65 per 
cent of the cost of ‘comfort’ drugs. But such disincentives are, 
as previously noted, normally offset by co-insurance. 
Future opportunities
In France the ONP (Ordre National des Pharmaciens) does 
not appear to be under pressure to change its ways of working 
through, for example, surrendering its regulatory functions to 
an independently run extra-professional organisation. There 
seems to be confidence that despite initial pressure from the 
European Commission to ‘de-regulate’ community pharmacy 
ownership, unwelcome changes can and should be resisted 
by the profession. 
This finding is consistent with the public opinion data 
presented earlier. Yet it should not be taken to imply that 
either the public or pharmacists are uniformly resistant to 
changing professional practices, or to finding new ways 
of working with partners in the medical profession or the 
pharmaceutical industry. Although some respondents 
rejected any idea that research based or other pharmaceutical 
companies could usefully help pharmacists to develop new 
clinical competencies, others were (cautiously) open to such 
possibilities. 
One also said it would helpful if pharmaceutical industry 
partners could help members of the pharmacy profession 
to be better informed about professional practice and 
pharmaceutical care developments elsewhere in the world. 
A possible conclusion to draw here is that in France further 
progress towards an enhanced role for community pharmacy 
is most likely to be achievable if it can be seen to be aimed 
at building on the strengths of what is arguably already one 
of the world’s best – if also more expensive – health care 
systems. 
Community Pharmacy in Germany
The health care context
Germany was re-unified in 1990. It is today a federal 
democratic state with a total population of approaching 83 
million. It has a higher proportion (19 per cent) of people 
aged over 65 years than almost any other EU member state. 
Life expectancy is similar to that in the UK, at almost 77 years 
for men and 82 for women. As in the rest of the Union the 
German health and social care system is having increasingly to 
provide services for people living with long term conditions, 
while also meeting the needs of other groups. Total health 
spending accounted for a little under 11 per cent of GDP in 
2005. For the purposes of this analysis it can be considered 
as equivalent to the French level of investment.
Below the national government level, the Lander (local 
government regions, with populations averaging around 5 
million) have responsibilities in areas such as public health, 
health service planning and supervising and supporting local 
pharmaceutical companies. They can invest directly in health 
facilities. But German health care is predominantly funded 
on what is normally referred to as the Bismarckian model. 
Just over three quarters of the population have compulsory/
statutory health insurance, known as the GKV (Gesetzliche 
Krankenversicherung). Close to half the remainder elect to 
use this system voluntarily. Almost all other Germans are 
covered by alternative public and private insurances. It is 
also mandatory for most people to have additional long term 
care insurance.
The GKV system functions via over 250 competing sickness 
funds (Krankenkassen). These finance care delivered by a wide 
range of independently run public and private hospitals and 
practitioners. At the professional level each Land has local 
chambers (membership of which is in many but not all cases 
mandatory) for groups such as community pharmacists. 
There are in total (including the national body) 17 pharmacy 
chambers that have what may be seen as a mix of economic, 
educational, regulatory and representative functions.
German health service users are, like their French peers, 
accustomed to high levels of choice and rapid access to good 
quality services. Figure 11 indicates that the level of acute 
beds per 1000 population provided in Germany has been 
in the order of three times greater than that funded in the 
United Kingdom. But as in other EU member states faced 
with ageing populations and intensified global competition, 
reforms introduced since the start of the 1980s have been 
aimed at containing costs and promoting greater efficiency 
in the German health sector. 
During the 1990s patient co-payment rates were raised in 
a number of areas. Out-of-pocket health outlays are about 
twice as high as those in France. This is partly because OTC 
medicine expenses are not reimbursable, even when they 
have been prescribed. (According to AESGP data, total non-
prescription medicine sales represented 17 per cent of German 
community pharmaceutical spending in 2006.) Further, 
although Germany has traditionally lacked general medical 
practitioners with a ‘gate keeping’ role, measures introduced 
in 2004 are encouraging the development of ‘home doctor’ 
(in essence GP) based systems. Nevertheless, health services 
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Figure 11. Beds in Acute Hospitals per 1,000 Population, 
1990 and 2003 or stated year.
Source: Glenngard et al 2005
Box 4. Towards the British Polyclinic
The UK has a strong heritage of independently 
located general medical practices. The doctors (GPs) 
in them act as the gateways to, and routing agents 
for, secondary care. All the other countries reviewed in 
this report have recently sought to emulate aspects of 
the established British primary care system. However, 
within Britain general practice has come under 
increasing challenge. 
Criticism may sometimes have stemmed from 
poorly informed political sources (the NHS is, many 
commentators believe, unduly politicised) and/or 
competing interests. Yet there are also technical and 
public interest reasons why the UK primary care system 
might benefit from reform. They relate to the needs of 
ageing populations on the one hand and the increasing 
benefits of medical specialisation on the other. 
Professor the Lord Darzi was appointed as a Minister of 
Health by Gordon Brown when he became UK Prime 
Minister in 2007. Lord (previously Sir Ara) Darzi is a 
celebrated surgeon, who immediately before joining 
the government had worked with the NHS to develop 
modernisation plans for London (Healthcare for 
London 2007). His proposals for the British capital 
can be summarised as involving a shift away from 
district hospital based care, towards greater use of both 
specialist centres and local polyclinics. It is envisaged 
that these last will serve populations of around 50,000 
people. If established, they will concentrate in the 
order of 20 GPs previously more widely dispersed 
in a single location, along with a similar number of 
specialist doctors and other health professionals.
It is presently uncertain how many new British 
polyclinics will be formed, and to what extent 
dispensaries or other pharmaceutical services will be 
located within them. Nevertheless, this UK example 
illustrates the types of solution to which twenty first 
century health care planners, seeking to provide cost 
effective care for patients with complex needs outside 
hospitals, may turn. For community pharmacists across 
Europe such trends present both the opportunity to 
become more directly involved in health care provision, 
and also what some see as the threat of incorporation 
into integrated community care organisations.
Yet some German pharmacists also said that problems of 
fragmentation and lack of care co-ordination remain relatively 
common, and that communication between doctors and 
community pharmacists is of variable quality. It was suggested 
that the quality of pharmaceutical care relating to variables 
such as checking prescriptions for contra-indications and 
possible drug interactions is not as consistent as was perceived 
to be the case in the UK and Sweden. One respondent with 
professional experience dating back to the time of East 
Germany said that although there are now significantly more 
pharmacies than there used to be in the GDR, and most people 
get an enhanced service, doctor/pharmacist communication 
was in her view better before re-unificiation. 
Structural and regulatory dimensions
There are around 21,000 pharmacies in Germany, each on 
average serving just under 4,000 people. Pharmacy locations 
are not officially controlled by any defined demographic or 
users are still able to contact specialists directly if they so wish, 
albeit that this can involve additional personal costs. 
In 2003/04 the largest insurance fund (Barmer Ersatzkasse, 
which serves about 9 per cent of the German population) 
introduced innovative contracts to incentivise community 
pharmacists to undertake ‘cognitive’ service activities such as 
medication reviews, and also to encourage patients to register 
with individual GPs and pharmacies (Eickhoff and Schulz 
2006, Blenkinsop and Celino 2006). Another illustration 
relevant to this context has been the funding by the apoBank 
(the Deutsche Apotheker und Ärztebank/German Pharmacists’ 
and Doctors’ Bank) of new polyclinics in cities such as Berlin, 
housing both pharmacies and medical surgeries. German 
polyclinic models served to inform the recent ‘Darzi’ review 
of primary and secondary care in England (Box 4). 
A Swedish pharmacist interviewed for this study commented 
that the contracting arrangements referred to above represent 
a potentially important development from not only a German, 
but a wider EU, perspective. This respondent argued that it 
provides an illustration of how in future primary care medicine 
and community pharmacy might across the Union be enabled 
to work together in more efficient and effective ways. 
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allied criteria, although only pharmacists can own pharmacies. 
Respondents suggested that professionally applied pressures 
may limit competitive and other behaviours judged locally 
as being undesirable. The formation of pharmacy chains is 
not permitted, although since 2004 an individual pharmacist 
or pharmacy partnership has been able to own up to three 
additional branch pharmacies within a given district.
Other changes introduced at that time deregulated OTC 
medicine retail prices, and permitted authorised pharmacies 
to supply prescription and other medicines via the internet. 
Most community pharmacies now have websites. But the 
extent of price competition between pharmacies in areas such 
as OTC medicine supply seems in practice to date to have 
been very limited (Stargradt et al 2007). Only about one per 
cent by value of pharmaceutical sales in Germany take place 
outside pharmacies.
In total around 140,000 people are employed in German 
community pharmacies, including some 46,000 pharmacists. 
Only pharmacists and qualified pharmacy technicians can 
dispense medicines. Community pharmacists are obliged to 
substitute generic for branded products unless this is opposed 
by the prescribing physician.
Since 2004 pharmacists’ profit margins on prescription 
medicines have been fixed at 3 per cent, plus a payment of 
just over 8 Euros per dispensed item. This has made German 
community pharmacy’s financial basis more transparent in 
that (as has for some time been the case in Denmark) it should 
in effect have removed pharmacy earnings attributable to 
privately negotiated medicines discounting, even if in some 
instances there are still additional pharmacy earnings.
Pharmacists interviewed for this report drew attention to the 
fact that some insurance funds now make direct contracts 
with manufacturers and/or wholesalers and importers for 
the purchase of selected medicines at low prices. This can 
generate savings, although problems are created when 
pharmacies cannot be supplied with adequate volumes of 
low cost product. Pharmacists expressed particular concerns 
about the imposition of additional paperwork. 
As it has also done in France, the European Commission 
recently questioned the legality of the pharmacy ownership 
regulations in Germany. Private action taken by a major 
German wholesaler (Celesio – which now owns the successful 
internet pharmacy Doc Morris) has also challenged the current 
arrangements. Representatives of organisations such as the 
ABDA (Bundesvereinigung Deutscher Apothekerverbände, the 
Federal Union of German Associations of Pharmacists) appear 
confident that the European Court of Justice will (in 2008) find 
in favour of the present ownership rules. Yet some respondents 
appeared less certain than their French counterparts that 
these regulations will endure indefinitely. One pharmacist 
suggested that the case for controls on pharmacy locations, 
and protecting standards of medicines access in poorer as well 
as more prosperous localities, might be stronger than that for 
limiting the ownership of pharmacies to pharmacists. 
In the context of the wholesaling sector, respondents 
reported mainly good relationships between wholesalers and 
pharmacists. Yet the German pharmaceutical supply system 
has become increasingly concentrated in recent decades. Two 
of the EU’s three largest companies operating in this area are 
German based. From their perspective it may seem anomalous 
that although they are permitted to own pharmacies in other 
parts of the European single market, this is not so in their home 
market. At the same time some pharmacists may be becoming 
more critical of large wholesale suppliers of medicines.
Pharmacy practice developments
Eickoff and Schulz (2006) have argued that German 
community pharmacies are moving from being seen as 
principally drug suppliers towards becoming providers of 
‘cognitive’ pharmaceutical – or more generally health care 
– services. These authors state that the latter have been 
developing in Germany since the early 1990s, when the 
ABDA first published a concept paper on this topic. In 
addition to the contractual innovations already referred to 
they noted educational and allied advances in areas such as 
asthma, diabetes, coronary heart disease, hypertension and 
case management.
However, against this background pharmacists interviewed 
pointed to a number of restraints limiting progress in this 
area. The topics respondents raised included:
•	 the medical profession’s concerns. It was stressed 
that unlike the situation in the UK, there is no shortage of 
medical labour in Germany. Doctors are perceived as being 
worried that an extension of community pharmacy’s role 
in clinical care could undermine their own employment 
and/or incomes. This is probably why one individual with 
a representative role was anxious to underline the point 
that ‘we are talking about extending the complementary role of 
pharmacy to medicine, not in any way replacing doctors’. Yet 
if no labour substitution related efficiency gains exist the 
economic case for extending pharmacists’ roles is weaker 
than could otherwise be the case;
•	 hospital pharmacy. Respondents expressed mixed 
views regarding the development of clinical pharmacy in 
Germany hospitals. Some saw it as well advanced, while 
others were more cautious in their assessment. It was 
pointed out that a proportion of smaller hospitals still do 
not have pharmacies of their own, and have contracts to 
be supplied with medicines by community pharmacies. 
This from a competition perspective is another area of 
possible interest to the European Commission;
•	 robotic dispensing. This was said to have been legalised 
recently. However, respondents may in the main have 
been referring to the provision of automated dispensing 
machines in settings such as nursing homes. There 
was apparently little acceptance of the possibility that 
very large scale robotic dispensing plants (essentially 
sophisticated pharmaceutical warehouses) might obviate 
the need for a significant number of local community 
pharmacies. Frequent mentions were made of the value 
of individual professional advice at a face to face level;
•	 the development of electronic medical record 
cards. It was explained that a system of patient held 
smart cards is being developed, with the likely date 
of introduction being 2009/10. These will be able to 
carry prescriptions, and be ‘read’ in pharmacies. But it 
appears that there remains uncertainty as to the extent 
of the patient health/medical record that such cards will 
carry and/or make available to community pharmacists. 
Respondents referred on several occasions to medical 
and consumer/patient fears that the state might make 
inappropriate use of integrated health care records, and 
the importance the German public may consequently 
attach to personal record holding.
•	 legal restraints on the scope of pharmacy practice 
and the content of pharmacy education. It was 
said by several individuals that although pharmacists 
may extend their roles in risk factor and diagnostic 
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testing, there are in Germany legal limits preventing their 
role being taken forward into treatment because this is 
categorised as medical practice. Likewise, respondents 
suggested that there are legal barriers to evolving the 
content of pharmacy education towards meeting modern 
environmental needs. These remarks suggested that the 
German approach to such issues may differ from that 
found in countries such as the UK; and 
•	 pharmacists’ concerns and interests. Interviewees 
said that community pharmacists may fear that, if 
they extend their roles in areas such as not only taking 
blood pressure measurements but also recommending 
treatments, doctors might seek to extend their roles into 
dispensing. One possible response to this last concern 
is that there needs to be an objective, evidence based, 
approach to defining when it is in the public’s interest to 
retain a ‘check and balance’ system of medical prescribing 
balanced by pharmacist dispensing, as opposed to 
those situations when such safeguards have become 
redundant. 
Another rather different subject that emerged during the 
qualitative interviews conducted related to the supply of 
homeopathic treatments and herbal remedies. A number of 
respondents noted the importance of ‘nature’ and ‘natural 
treatments’ in the German public’s thinking about health. 
One individual linked this social fact with eighteenth and 
nineteenth century romanticism. Others appeared to be 
concerned with possible inconsistencies between modern 
critical thinking and more traditional approaches to 
pharmaceutical science. Herbal and homeopathic medicines, 
like all others, are sold for profit. However, it was suggested 
by one respondent that although German pharmacies are 
presently legally obliged to offer a full range of such remedies, 
consumer access to such products might be reduced if 
‘commercial chains’ were allowed to operate.
Pharmaceutical cost controls
The German pharmaceutical market is the largest in Europe. It 
accounts for about 1.6 per cent of GDP at manufacturers’ prices. 
In 2004 German medicine expenditures (at manufacturers’ 
selling prices, and including both prescription and non-
prescription products) stood at about £280 per capita, 
compared with £320 in France, circa £240 in Sweden and the 
UK, £170 in Greece and £70 in Poland (OHE 2007). The factors 
underlying the differences between European pharmaceutical 
sales figures involve not only product price and volume 
use variations, but also currency fluctuations. The German 
approach to medicines cost limitation has embodied a variety 
of measures, including:
•	 reference pricing (in which ‘baskets’ of generic, branded 
and – from 2005 – patented medicines thought to be of 
similar therapeutic value are allotted common prices, over 
and above which the consumer must pay the surplus); 
•	 a negative list (covering medicines such as OTC products 
that are excluded from reimbursement); and 
•	 the imposition of prescribing cost limits or budgets for 
practitioners, which if exceeded require doctors to pay 
penalties. 
The German Federal authorities have also supported the 
creation of a national body for – like NICE – producing cost 
effectiveness based prescribing guidelines. The Institute for 
Quality and Efficiency in Health Care (IQWIG) was established 
in 2004. 
Reference price based approaches have been criticised for 
keeping off-patent medicine prices relatively high, while 
depressing returns on patented products. It is also relevant to 
note that German sickness funds have positively encouraged 
the use of low cost parallel imports from poorer parts of 
Europe, and that German health service users typically 
have to make out of pocket payments for both accessing 
primary care doctors and receiving prescription items, as 
well as for purchasing OTC products. (As previously noted, 
OTC medicines are not – even when medically prescribed 
– reimbursable.) Pharmaceutical co-payments represent about 
10 per cent of total pharmaceutical outlays, with a ceiling 
charge per pack of 10 Euros.
Future opportunities
Notwithstanding unique national cultures and differing 
health care systems, community pharmacy in France and 
Germany enjoys a number of common characteristics. The 
two pharmacy models are more like each other than either 
is similar to that of the UK. This is most obviously so with 
regard to the regulations which have until recently prohibited 
all multiple pharmacy ownership, and the extent to which 
pharmacies are the exclusive suppliers of medicines in their 
local communities. The pharmacist’s role has been, and 
remains, sharply divided from that of the doctor in both 
countries.
Yet the qualitative evidence gathered during the survey 
reported here suggests that today the pressures on German 
community pharmacists to adapt their roles and patterns 
of practice are greater than those found in France. German 
respondents seemed to be less confident of community 
pharmacy’s ability to resist further change (following the 
reforms already introduced in 2004) than their Gallic peers. It 
also appears that the German pharmacy community is more 
aware of international pharmaceutical care developments, 
and more open to considering their significance in relation 
to future domestic service improvements. In the case of 
incentivising closer integration of medical and pharmaceutical 
inputs to primary care Germany can already be regarded as 
a European leader, although (as with some UK innovations) 
the extent of substantive service change should not be 
exaggerated.
Some of those approached during the course of this 
research appeared hostile to the pharmaceutical industry, 
particularly in the context of possible further developments 
in pharmaceutical distribution processes. Rightly or wrongly, 
industry attempts to increase supply chain security and 
economic efficiency may on occasions have been seen as 
attempts to reduce pharmacy earnings, and/or to change 
German pharmacy ownership regulations. One respondent 
said ‘it would be better for pharmaceutical companies to leave 
pharmacy development to pharmacists (in the pharmacy 
chambers), and concentrate on spending less on drug promotion 
and cutting prices.’ 
But others were more open to the idea of working with 
pharmaceutical companies further to develop pharmaceutical 
care competencies and services. Another pharmacist 
commented ‘whatever is said in public pharmacists are in many 
ways dependent on the companies that make medicines, and they 
co-operate with them in private.’ This respondent said that if 
both ‘sides’ want to make a contribution to improving health 
in Germany via pharmacy based service developments, then 
opportunities for closer joint working could be found. 
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Community Pharmacy in Greece
The health care context
Greece has a population of 11 million, with levels of infant 
mortality and male and female life expectancy equivalent 
to, or marginally better than, those recorded in Germany 
and the UK. This achievement has in part been associated 
with the traditional Mediterranean diet, and differing 
historical patterns of alcohol and tobacco use. However, life 
style changes associated with increasing wealth and (some 
observers believe) a lack of pro-active health promotion may 
now be undermining some of these health advantages.
Total spending on health care in Greece stands at about 10 
per cent of GDP, just under a half of which is classified by 
the OECD as being public expenditure. Other sources of 
health care funding include private insurance, and out-of-
pocket outlays. It is alleged that there is a substantial health 
care ‘black market’ in Greece. This involves people making 
personal payments to doctors, sometimes for prioritised 
access to or special attention during hospital care. (This can 
be compared with the custom found in Poland of patients 
making ‘envelope’ payments to doctors – see below.) Such 
phenomena can interact with factors such as inequalities in 
publicly funded health care provision between richer and 
poorer, and rural as opposed to urban, communities. (See, for 
example, Tountas et al 2002, Kontodimopoulos et al 2006). 
The Greek National Health System (the ESY) was established in 
1983. As in Germany, there are a range of alternative sickness 
funds. The Greek system has in recent years undergone (like 
virtually all other EU member state’s health sectors) a series of 
reforms aimed at creating a ‘managed market’ and improving 
overall efficiency and effectiveness. But it appears that 
problems continue to exist. Some respondents said that the 
Greek health care system is undesirably fragmented. General 
practice remains relatively poorly developed, and referrals to 
secondary care are channelled via a variety of routes. 
Figure 12. Practising Physicians per 1,000 Population, 
2006
Source: OECD 2007
(1) 2004  (2) Physicians entitled to practise
The proportion of nurses relative to doctors working in 
Greece is unusually low. Figure 12 indicates that the number 
of practicing physicians per 1000 population is the largest 
in the OECD. While this may offer some advantages, a very 
high medical to nursing manpower ratio might reflect a lack 
of adequate service planning and management. 
In the context of primary health care, attempts have since 
the start of the 1980s been made to establish a family doctor 
based system. But these have not been particularly successful. 
Community medical services remain provided via a complex 
mix of ESY and separate social insurance and local authority 
funded polyclinics, complemented by large numbers of 
community office based private specialist and generalist 
practitioners. Better off people may have a range of physicians 
that they visit as and when they judge it necessary.
There is evidence of public dissatisfaction with elements the 
Greek health care system, as in the UK there is in relation to 
aspects of the NHS. But one respondent (a pharmacist with 
experience of practice in and also being a patient in both the 
UK and Greece) warned against underestimating the Greek 
approach. This individual said ‘I have used both (the NHS and 
health services in Greece) and I know that I get to see a doctor 
more quickly in Greece – for (people like) us is no waiting about 
for days or weeks without care.’
This interviewee went on to describe making a personal 
payment to a surgeon in relation to an operation for a family 
member. He commented ‘its almost a fixed rate – you know how 
much is expected. But doctors vary what they charge if people are 
poor. I think our (Greek) system works well, especially if you take 
into account differences in families.’
Structural and regulatory dimensions
As with the number of practising doctors, the number of 
community pharmacies per capita in Greece is the highest 
in Europe. There is one community pharmacy per 1100-
1200 population. Against the background described above, 
the population has good access to pharmacy and to most 
medicines. The controlled prices of the latter are relatively low. 
Out-of-pocket pharmacy outlays on OTC products account for 
less than 10 per cent of the community medicines market in 
Greece (AESGP 2007). As in France, this is probably a function 
of medicines supply being largely funded via insurance. 
However, Greek pharmacists interviewed also indicated that, 
subject to professional judgement, prescription medicines are 
much more commonly supplied without prescription than is 
so in countries such as Germany, France and the UK.
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Any pharmacist, or pharmacy partnership, can own a 
pharmacy, and pharmacies must be independent of each 
other. Chains are not permitted. Before 1997 there were no 
restrictions on the number of Greek community pharmacies, 
and the average number of people per pharmacy fell to 
only 900. This led to the application of new geographic and 
demographic criteria to the control of pharmacy openings. In 
Greece licensed medicines can only be sold in pharmacies, and 
internet pharmacy is not officially allowed. Only pharmacists 
can legally dispense.
The Greek wholesaling sector remains less concentrated than 
that of northern Europe. Respondents reported that there is 
strong competition between wholesalers, and normally good 
relationships between them and pharmacists. Pharmacists’ 
co-operatives were said by one well placed respondent to 
supply just over 50 per cent of the total market. However, 
there have been reports of domestic medicine shortages (and 
some reported thefts), in part caused by the high proportion 
of medicines supplied to the Greek market being exported out 
to other parts of the EU through parallel trading. 
Community pharmacists receive (via the circa 30 sickness 
funds that underpin the Greek health care system) a flat rate 
mark-up of 35 per cent on the wholesale price of the medicines 
they supply to ESY patients. This is broadly comparable to 
the private OTC and other medicines sale margins made in 
Greece and other EU countries. Respondents also said that 
relatively small additional discounts may be available from 
wholesalers.
The use of generic medicines has not been encouraged in 
Greece, and generic substitution is not permitted. Some 
pharmacists and pharmaceutical policy analysts question the 
apparent inconsistencies in national policy in this area, with 
its focus on low pricing of new products but relatively lax 
approach to generic prescribing. Respondents suggested that 
savings could be made if pharmacists were able to substitute 
generic or other cheaper versions of branded medicines. 
It was also suggested that inappropriate payments are not 
infrequently made to doctors who prescribe relatively costly 
products, not only by commercial representatives but also by 
some dispensing pharmacists.
Pharmacy practice developments
Following on from the above, some responses given during 
this research by Greek pharmacists were indicative of tensions 
between themselves and members of the medical profession. 
It was said, for example, that when community pharmacists 
identify prescribing errors they have to be very careful not 
to give any indication of a possible error having been made 
to the patient. This (it was said) might risk medical anger 
and retribution. The interests of the medical profession were 
frequently seen as a factor which, along with other health 
service variables, has limited the appropriate development 
of clinical pharmacy outside some military and specialist 
hospital settings.
Little evidence was found that community pharmacy in 
Greece is moving formally towards adopting an extended 
clinical and/or medicines management role such as that 
being pursued in the UK. Yet work has been undertaken in 
fields such as providing patients with improved information 
about prescribed products and encouraging safe and effective 
self medication. Some respondents said they have a wider 
health care role ‘unofficially’. It was noted that community 
pharmacists in Greece commonly give injections, measure 
blood and tend to people who have had accidents, albeit that 
one pharmacist also complained of being little more than ‘a 
dispensing machine’.
Respondents were not generally aware of any developments in 
relation to the establishment of large scale robotic dispensing 
centres. But one more centrally placed interviewee mentioned 
an electronic prescribing pilot scheme, and plans to in 
future allow the consolidation of primary medical care and 
pharmacy information. Patients hold unique social insurance 
numbers, and it was suggested that using these might in time 
permit a smart card based personal health record system 
to be developed. Many Greek pharmacies already hold 
computerised records of medicines received by named service 
users. Respondents said that local record linkage initiatives 
were more likely to succeed than a nationwide programme
It appears unlikely that there will in the foreseeable future 
be progress towards formal pharmacist (or nurse) prescribing 
of prescription medicines in Greece. Nevertheless, Greek 
community pharmacists (perhaps especially those serving less 
advantaged communities) seem in some respects to be more 
closely involved in the direct delivery of health care to service 
users than are their peers working in other western Europe 
settings. Respondents expressed high levels of confidence 
about the extent to which the Greek public values community 
pharmacy, and the quality of the relationships that exist 
between pharmacists and pharmacy users. This is consistent 
with the quantitative data presented earlier in this report.
Pharmaceutical cost controls
At present Greek pharmacy incomes are directly related 
to the cost of medicines supplied. Total Greek outlays 
on pharmaceuticals account, at manufactures prices, for 
approximately 1.7 per cent of the GDP (OHE 2007). This 
is comparable to the equivalent proportion for Germany, 
although in per capita outlay terms Greek spending is half 
the German figure. Taken together, these data may be taken 
to imply that the lower level of national wealth in Greece as 
opposed to, say, Germany has been to a degree compensated 
for by lower pharmaceutical prices. Nevertheless, population 
wide access to products like new anti-cancer agents is better 
in countries such as Germany and France, and there appear 
to be avoidable costs in the Greek pharmaceutical supply 
process associated with local vested interests.
The Greek approach to pharmaceutical price control has 
historically rested on analyses of the prices charged elsewhere 
in the EU and the selection of the lowest comparators, 
supplemented by the imposition of an additional discount. 
In the case of new medicinal products today Greek prices 
are normally determined on the basis of the three lowest 
prices found in the EU, including two from the original 
EU 15 nations and an additional one from one of the 2004 
acceding countries. All the Greek sickness funds impose a 
uniform 25 per cent co-payment on prescription items, except 
for treatments for patients with chronic or life threatening 
illnesses. In the latter instances treatment is free, or there is 
a limited co-payment of up to 10 per cent. 
Future opportunities
Greece and the UK can perhaps be seen as occupying opposite 
ends of the (western) European pharmacy, and wider health 
service, spectrum. While public expenditure on the NHS 
dominates the UK health sector, private insurance and related 
outlays fund over a half of all Greek health care. Britain 
permits relatively high prices for innovative pharmaceuticals 
but strongly encourages generic prescribing and cost saving 
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molecular substitutions, and is a large scale parallel importer 
of medicines. By contrast, Greece has lower imposed prices 
but has not fostered generic prescribing or substitution. It is 
also one of Europe’s largest parallel exporters of medicines. 
Further, while Greece has the highest relative numbers of 
doctors and community pharmacies per capita in Europe, 
the UK has low numbers of both. However, despite these 
marked structural differences pharmacist interviewees from 
the two countries appeared to share some common views, 
in part because of a mutual belief that given appropriate 
support pharmacists could contribute more to improving 
the public’s health. 
The Greek pharmacists who contributed to this survey 
appeared relatively open to the concept of working with 
pharmaceutical industry partners in order to take forward 
pharmaceutical care. Opportunities discussed included 
providing opportunities for relevant competency training 
and the development of community pharmacy ‘disease 
management’ and medicines taking adherence support 
programmes in fields such as cardio- and cerebro-vascular 
disease risk reduction. The possibility that research based 
pharmaceutical companies might support attempts to enable 
Greek pharmacists to gain powers to conduct (and appropriate 
payments for) generic substitution was also mentioned.
Ultimately, all stakeholders in the appropriate use of new 
and existing medicines should benefit from coherent 
financial incentives and regulations aimed at promoting 
ethical behaviour, and optimising all aspects of prescribing. 
In circumstances where such incentives have yet to be 
fully established, practice and policy distortions could at 
worst adversely affect not just the populations of individual 
member states, but the wellbeing of the Union as a whole. 
With regard to medicines supply and use in Greece, one topic 
to be considered in this context is that of pharmaceutical 
parallel trading in Europe. The latter has impacts on patients, 
health care and pharmaceutical industry funded activities 
throughout the EU. 
Community Pharmacy in Poland
The health care context
Poland has shared with eastern Germany direct experience 
of the fall of communism, and since 2004 has faced the 
challenges and opportunities of national re-establishment 
within the single European Union market. Poland’s political 
and economic situation has affected significantly both public 
health and health sector development. The country’s health 
service has undergone a series of troubled reforms in the 
past decade, which first established a system of sickness fund 
based compulsory health insurance and subsequently created 
a centralised National Health Fund (NHF). More recent 
governmental changes have interrupted planned reforms to 
the law relating to pharmacy.
Tensions between locally managed, non-market, approaches 
to health (and social) care provision and national level 
attempts to establish a competition driven ‘managed market’ 
have, as in other European settings, limited progress. In 
2007 Polish doctors took high profile industrial action, 
complaining of both low pay and poor working conditions. 
Individuals contributing to this research suggested that 
some medical interests are in addition opposed to changes 
within the health sector, and a perceived diminution of their 
professional influence. 
The current Polish population is 38 million. However, because 
of low birth rates and extensive emigration some projections 
suggest that it could fall to 30 million by 2050. The proportion 
of people aged over 65 years is low in western European terms, 
at 13 per cent. Average life expectancy is also relatively low, 
at 71 for men. For comparison, the equivalent Greek figure 
is about 77 years, and that for Sweden 79 years. 
Total Polish spending on health stands at just over 6 per cent 
of GDP.  This too is low in western European terms. About 25 
per cent of all Polish health outlays take the form of private 
expenditures (European Observatory on Health Systems and 
Policies 2005). Despite a developing private insurance system, 
these last frequently involve out-of-pocket expenses for items 
such as medicines. 
As in Greece, it is also reportedly still common for Poles 
seeking hospital care to make additional personal payments to 
doctors (‘envelope payments’ – see McMenamin and Timonen 
2002). But long queues and difficulties in accessing specialists 
are much more frequently found in Poland.  Respondents 
to the survey reported here and published sources suggest 
that levels of dissatisfaction with access to, and the quality 
of, health care are higher in Poland than any of the other 
countries discussed in this pharmacy report.
Historically, the origins of the Polish health care system date 
back to a limited Bismarckian social insurance framework 
established in the first half of the twentieth century. This was 
followed from the 1940s onwards by a Soviet care model. The 
quality and extent of the services this offered varied widely 
between urban and rural areas. Agricultural workers in particular 
had only limited access to publicly funded services (Millard 
2007). The most extensive publicly funded resources were found 
in cities serving as political and military power centres.
In towns in particular, the predominant model for community/
primary medical services involved specialist physicians such 
as paediatricians, gynaecologists and specialists in internal 
medicine working in polyclinics (Przychodnia). However, since 
1991 there has been an increasing emphasis on developing 
generalist based ‘family medicine’ more like that found in 
the UK, and a relative reduction in the provision of hospital 
beds. Despite some shortages of medical labour in Poland, 
there are today approaching 10,000 doctors qualified in family 
medicine. There are also some 10,000 community pharmacies in 
Poland. These were privatised at an early stage in the country’s 
post communist development era, and seem – according to 
interviewees – to have occupied a relatively stable place within 
the national health care environment. Respondents to this 
survey said that the social and professional status of pharmacists 
is relatively low. The economic position of community pharmacy 
owners in Poland appears to be more satisfactory. 
Progress towards extended pharmaceutical care provision 
has so far been limited. One respondent commented ‘you 
(UK observers) should think of us being where you were in the 
1960s’. Employee pharmacists (and technicians) have stable 
but in western European terms low earnings. Interviewees 
complained of high dispensing workloads, boredom and 
isolation from both other health professionals and patients. 
Dispensing areas, it was said, commonly have glass or other 
screens separating them from the public. One respondent 
(who worked with a Polish owned chain pharmacy) 
commented ‘the money comes from the medicines. We would 
like to give patients advice but it depends on good will and the 
time we have – we are not paid to do it’. 
Community pharmacy was also said to be ‘a good job for 
modern women’, apparently because of the combination of 
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low but stable pay and predictable working hours that permit 
family responsibilities to be met. Others noted the willingness 
of the Polish political establishment to listen to advice given 
by members of the professional chambers. (The organisation 
of pharmacy as a profession is similar to the system in place 
in Germany.) This is perhaps partly because pharmacy may in 
the Polish context be perceived as a possible counterbalance 
to medical power, although respondents indicated that in a 
some instances community pharmacies and medical practices 
are successfully co-located.
Structural and regulatory dimensions
The average population per community pharmacy is between 
3,500 and 4,000, although between urban and rural districts 
the ratios vary between 1:1,000 and 1:>5,000. (In rural areas 
pharmacists may be offered higher salaries to attract them to 
live there.) In Poland anyone, pharmacist or not, can own 
a pharmacy. There are limited opportunities to establish 
chains, albeit that no one individual or company can (as from 
2004) own more that one per cent of the pharmacies in each 
region. As in Germany, there are 16 of the latter. However, 
respondents said that independent pharmacies can form 
coalitions for purposes such as purchasing. (Before 2004, the 
year in which Poland joined the EU, individuals or corporate 
bodies could own up to 10 per cent of the pharmacies in 
any one region. The change in this regulation was not 
retrospective, so existing ‘indigenous’ wholesaler and allied 
interests in pharmacy ownership were not affected.)
Most Polish pharmacies are, like others in the EU, computerised 
for purposes such as stock control and ordering. They 
may also communicate and trade with customers via the 
internet, although ‘foreign’ pharmacies are prohibited from 
supplying the Polish market via this route. It was estimated by 
interviewees that about a quarter of community pharmacies 
have functional access to the internet.
Polish pharmacists (who have five years education) have 
full dispensing rights. Pharmacy technicians (who have two 
years training) have limited rights, subject to pharmacist 
supervision. In practice, however, some respondents said that 
technicians may dispense independently. Polish pharmacists 
can substitute generic for branded medicines. Some general 
sales medicines can be sold by any retailer, but the majority 
of OTC (as well as prescription) pharmaceuticals are only 
available from pharmacies.
Around 80 per cent of Polish community pharmacies remain 
in the hands of individual owners, with the remainder 
being owned by wholesalers. There are over 500 of these last 
registered. Respondents explained that pharmacy proprietors 
may have interests in them via, for example, their local 
professional chambers. 
This suggests that the pharmacy market in Poland (which 
like that of most other countries is split into hospital and 
community sales on a roughly 1:4 basis by value) is less 
concentrated than is so in countries such as France, Germany 
and the UK. Yet some estimates indicate that the top three 
wholesalers already supply over 80 per cent by value of all 
medicines. The wholesale price of medicines in Poland is set 
at 10 per cent above the producer’s price, and in the case of 
low cost items retail prices are up to 40 per cent above the 
latter. Permitted margins on more expensive products are, 
however, significantly lower.
WHO data indicate that reimbursed medicines account for 
around a half of the community market. OTC medicines paid 
for directly by consumers account for between 25 and 30 per 
cent by value, and the remainder is made up of prescription 
medicines purchased privately by customers. Pharmacists 
interviewed indicated that POM medicines such as antibiotics 
and psychotropics with a potential for abuse are not normally 
supplied without a prescription. But other treatments, 
respondents said, can be supplied directly by pharmacists 
within a protocol based framework. It was emphasised that 
in these instances the customer pays the full cost.
Given that patients also make co-payments for reimbursed 
medicines, approaching two thirds of all pharmaceutical 
outlays are met privately in Poland. Factors such as the 
apparent preference of the Polish public for purchasing 
‘natural’ herbal and allied treatments, should perhaps be 
taken into account. But this is by far the highest proportion 
found in the national markets considered in this report. Such 
data may help to explain why the Polish market also has the 
highest proportion of generic medicines use observed (EGA 
data suggest that almost 80 per cent by volume and 60 per 
cent by cost is supplied in generic form – Figure 13) and why 
Polish respondents noted the existence of active medicines 
price competition between community pharmacies. One 
emphasised ‘the big issue for people here is the cost of medicines. 
People are worried they cannot afford treatments they need.’
Figure 13. Pharmaceutical Market Shares Accounted for 
by Generic Medicines, Europe, 2006
Source: EGA 2007
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Pharmacy practice developments
Van Mil and Schulz (2006), in their pioneering study of 
pharmaceutical care development in Europe, noted that 
since 2001 Polish pharmacists taking part in national and 
international conferences have displayed an active interest in 
the idea of pharmaceutical care. Yet they also observed that it 
seems that the pharmaceutical care concept has not in reality 
penetrated practice. This study confirms that conclusion. 
It is also apparent that only very modest progress has been 
made towards the development (and less so the effective 
sharing between medicine and pharmacy) of electronic 
care records in Poland, and that possibilities such as the 
electronic transmission of prescriptions from medical centres 
to pharmacies have not widely been explored.
Respondents did not – although they were aware of the 
possibility – see the introduction of robotic dispensing plants 
as being likely in the foreseeable future. Communication 
between community pharmacists and family and other 
doctors working in health centres was said to be very 
limited, although a pharmacist with experience of working 
in a rural setting in Poland did mention collaboration 
with a local doctor. Nevertheless, ‘high level’ professional 
activities identified during this project suggest that the Polish 
pharmaceutical leadership is beginning to address issues such 
as how to create financial incentives for the development 
of health promotion and care services in pharmacies. Pilot 
work on diabetes and the pharmaceutical care of people with 
hypertension was mentioned, and respondents indicated 
that robust efforts were being made to learn from these 
initiatives.
Pharmaceutical cost controls
The Polish health care system operates both positive and 
negative lists of medicines that are permitted and excluded 
for reimbursement purposes. Pricing applications for new 
products are made to the Ministry of Health.  The submitted 
data relate to production and usage costs, sales levels, efficacy 
and effectiveness in both pharmacological and public health 
terms, and selling prices in other comparable markets. If 
accepted for NHF reimbursement for either general supply 
or to patients with defined conditions, patient co-payment 
levels may be set at a number of levels, ranging from a flat 
fee of less than one Euro through to up to 50 per cent of the 
product’s retail price.
Poland’s per capita spending on hospital and all community 
medicines is, when costed in manufacturers’ price terms, only 
£70, compared with a French figure of five times that sum. Yet 
when calculated on the same basis the proportion of Polish 
GDP devoted to medicines (1.9 per cent) is almost the same 
as that spent in France, and the proportion of total health 
outlays accounted for by pharmaceutical costs is almost twice 
that recorded in France. Even allowing for discrepancies 
between data sources and other factors, this is indicative of 
major imbalances between EU member states that are unlikely 
to be corrected in the foreseeable future.
There is an evident under-investment in health care in 
Poland. Despite the widespread use of low cost generic 
products, the Polish population does not receive the quality 
of pharmaceutical treatment enjoyed in more prosperous 
countries. This observation has important implications for 
European Union pharmaceutical policies, and issues such as 
the desirability or otherwise of current and possible future 
patterns of EU parallel trading in medicines. The policy 
justification for the latter is that it will help harmonise living 
standards and promote growth. But in the case of Poland the 
population will be disadvantaged if medicine prices other 
than those of generics were to be set at levels that would be 
appropriate in western Europe.
Future opportunities
Currently, the development of Polish community pharmacy 
lags behind that observed in more affluent parts of the EU. 
However, there are some aspects of the Polish situation 
which could help promote the future development of clinical 
pharmacy in community settings, and pharmacy based health 
care. They include:
•	 the limited availability of medical manpower in Poland 
(which might currently in part be associated with skilled 
labour movements to other parts of the EU);
•	 tensions between politicians and the medical profession 
relating to health care funding and management, that 
may have helped increase governmental awareness of 
the capacity of pharmacies to provide health related 
services; 
•	 reportedly high levels of service user dissatisfaction with 
medical care access and service choice;
•	 unmet public health related needs, as evidenced by – for 
instance – Poland’s low average life expectancy figures; 
and
•	 a relatively flexible regulatory tradition. This is illustrated 
by the fact that pharmacy ownership rules have not been 
as prescriptive in Poland as in many other European states, 
and that forms of protocol based pharmacy prescribing 
already appear to exist.
The current situation in Poland is clearly challenging, and 
the speed at which genuinely constructive progress could be 
achieved should not be over-estimated. But neither should 
the differences between pharmacy in Poland and countries 
such as the UK be exaggerated – the comments reported 
here about dissatisfaction within the profession are in 
reality not that far different from the experience of many 
younger British pharmacists (Taylor and Carter 2002). Taken 
together, the points above suggest that if Polish community 
pharmacy leaders seek in a sustained and informed manner 
to extend their pharmaceutical and wider health care roles 
in ways consistent with the public’s needs and preferences, 
they should in time succeed. This finding reinforces the 
implications of the public opinion research presented in the 
first section of this report. 
Community Pharmacy in Sweden
The health care context
The population of Sweden is 9 million. Of this total over 17 
per cent are aged over 65. Swedes arguably enjoy the most 
sophisticated welfare state provisions available anywhere 
in the world, and have amongst the longest recorded life 
spans. Men live on average for 79 years, and women for 83 
years. Total Swedish health expenditures are just above the 
OECD average of 9 per cent of GDP, on top of which there 
are some additional outlays on social care. Health and social 
care is mainly funded via personal income tax, together with 
a payroll tax levied on employers.
The current version of the Swedish health service dates 
back to legislation introduced in 1982. This committed the 
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country to providing universally available, high quality and 
cost effective care, on the basis of need rather than ability to 
pay (Glenngard et al 2005). As with the UK NHS, optimising 
population health is the system’s primary end. 
Since the start of the 1980s there have, as with the other 
national systems reviewed here, been a series of complex 
reforms aimed at limiting the growth of health spending 
and improving efficiency. The Swedish system operates 
at three distinct levels. Central government sets overall 
goals. Beneath this, the 21 regional County Councils and 
related administrations deliver health services, and have 
from 1998 been responsible for holding drug budgets 
previously administered nationally. (Decentralised facility 
level pharmaceutical budgets were introduced at around the 
same time: they appear to have increased medicines cost 
awareness amongst GPs/primary care practitioners – Jansson 
and Anell 2006.) 
Finally, the 290 local municipalities provide social care to 
individuals with, for example, long term conditions that 
have in medical terms been effectively treated. Sweden has 
strong local government and co-operative traditions, and 
this separation of functions is regarded as a positive strength. 
Sweden, like the UK, operates with, in European terms, an 
exceptionally low number of acute hospital beds per capita.
During the past two decades Swedish health care planners have 
sought to strengthen the provision of general practitioner care 
in the community, and partly via the latter to manage health 
resource utilisation efficiently. As in the cases of Finland and 
Norway, Sweden operates with one of the highest nurse to 
doctor ratios in the world. Primary medical and nursing care 
is principally supplied via the country’s 1100 health centres. 
However, about a quarter of all primary care contacts are 
made in privately owned facilities. There is evidence that 
although older patients may have more complex care needs, 
they tend to prefer ‘traditional’ medical care based on personal 
relationships rather than the more anonymous interactions 
that may characterise large health centres (Anell 2007).
Pharmacy services have since 1970 been provided via a single 
nationalised agency called Apoteket AB (‘The Pharmacy’). This 
arrangement was found to be inconsistent with European law 
by a European Court of Justice ruling made in 2005 (Neroth 
2005), and it appears that the Apoteket monopoly will end 
in 2008. Nevertheless, the establishment and performance 
of the organisation offers a unique example of a unified, 
publicly owned, approach to pharmaceutical care in the 
community. 
Apoteket’s reported strengths in some ways parallel those of 
large pharmacy chains in countries such as the UK and the 
US. Contributors to the qualitative analysis offered here noted 
its capacity to develop corporate approaches to improving 
technical quality and taking forward the development of 
its services, and to limiting overall medicines supply costs. 
Combined community pharmacy and wholesaler mark 
ups/margins on prescription medicines account for only 20 
per cent (17 per cent pharmacy, 3 per cent wholesaler) of 
pharmaceutical costs in Sweden (Westerland and Bjork 2006). 
This is well below the European average. 
Apotoket’s advocates also stressed the organisation’s public 
service, as opposed to commercial, values. However, in 
regulated modern markets the validity of this distinction is 
questionable. It might even serve to conceal professional and 
other provider side interests that may sometimes be pursued 
at the expense of the public’s best interests. Critics of the 
Apoteket monopoly also say that is has reduced competition 
and harmed not only some medicine suppliers but more 
importantly patients, at least in contexts such as having 
both convenient and low cost access to non-prescription 
treatments. 
Structural and regulatory dimensions
There are in the order of 900 Apoteket pharmacies across 
Sweden’s 170,000 square mile land area. This is equivalent to 
one pharmacy per 10,000 people, for a geographically widely 
dispersed population. The Swedish community pharmacy 
infrastructure is supported by approximately 1,000 additional 
‘pharmacy representatives’ or apoteksombuds, which are non-
pharmacy outlets such as village shops that facilitate made up 
prescription distribution (Andersson et al 2002). But even so 
it differs radically from that observed in southern European 
countries like Greece. 
Individual Swedish pharmacies are normally larger than their 
counterparts in comparator nations such as France, Germany 
and the UK, and they employ a wider range of staff involved 
in dispensing and OTC medicines supply to the public. In 
addition to over 900 pharmacists, Apoteket employs about 
2,000 pharmacy technicians and 5,000 prescriptionists 
(receptarie). The latter undergo three year graduate courses, 
as opposed to the five years of research orientated University 
training received by pharmacists. 
Both pharmacists and prescriptionists can dispense. When 
employed in similar roles they earn similar amounts of money. 
However, pharmacists interviewed said that the managerial and 
clinical role development opportunities open to pharmacists 
are superior to those available to prescriptionists. Apoteket 
AB enjoys a monopoly over the sale of all medicines. Most 
OTC products can only be purchased in pharmacies, although 
pharmacy representatives offer a limited range.
Although OTC products account in total for only 9 per cent of 
Swedish community medicines use by value (AESGP 2007), all 
such medicines are paid for out of pocket. They consequently 
represent a significant private income stream for the Swedish 
nationalised pharmacy system. (Respondents to this survey also 
suggested that in the countryside in particular there is still – as 
in Germany and Poland – a relatively strong belief in ‘natural’ 
remedies, that are not necessarily purchased formally.)
Apoteket uses just two main wholesalers, Tamro and Kronans 
Droghandel. Internet pharmacy service provision is legal 
in Sweden, but as with conventional pharmacy care this is 
presently only available from Apoteket outlets. Medicines can 
already supplied through telephone ordering, and distributed 
via the Swedish postal service. But this presently accounts for 
only 2-3 per cent of medicines distribution.
Pharmacy practice developments
Individuals contributing to this study seemed confident that 
pharmacy practice in Sweden is highly advanced, and world 
leading in respect of not only aspects of hospital clinical 
pharmacy but also with regard to community delivered 
pharmaceutical care. This achievement was in large part 
attributed to the advantages for health professionals of being 
located in the settings provided by Apoteket. There was 
at the time interviews were being conducted (the summer 
and autumn of 2007) considerable professional concern in 
Sweden that reforms designed to introduce more competition 
could undermine this situation. None of the practitioners 
involved mentioned positive advantages to be derived from 
the opening of new private pharmacies.
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The information given by respondents, along with that 
obtained from the available literature on Swedish pharmacy 
(see, for example, Westerlund et al 2003, Westerlund and 
Bjork 2006), highlighted a variety of significant practice 
developments, including:
•	 the provision of self care support literature and 
the establishment of relevant practice quality 
and referral standards, together with the production 
by Apoteket of a nationally available magazine, covering 
health and pharmaceutical care related topics;
•	 the introduction of the ‘Health Points’ 
programme, which offers a variety of information and 
risk factor testing opportunities, plus pharmacy based 
lifestyle counselling and ‘health coaching’; and
•	 the establishment of a national computer based 
system for recording drug related problems 
(DRPs) in Sweden. A system for recording prescription 
medicine use on a patient by patient basis, that will – given 
patient permission – make relevant records available to 
both doctors and pharmacists, has also been instigated. 
Dealing effectively with patients’ problems in medicine 
taking was regarded by respondents as a central element 
of the pharmaceutical care (as distinct from more broadly 
defined health care) service that could be uniquely offered 
by pharmacists, as opposed to other professionals working 
in the Swedish system.
Interviewees were informed about issues such as the potential 
of electronic prescribing and robotic dispensing to offer 
new pharmaceutical supply opportunities. In the order of 
a third of all Swedish prescriptions are already transmitted 
electronically. One mentioned the possibility of allowing 
selected companies such as the US internet pharmacy 
Medco to compete with Apoteket. However, even if this were 
permitted, it would not in itself resolve problems relating 
to a lack of convenient physical access to OTC and/or 
prescription medicines. Other pharmaceutical sector policy 
experts suggested that Apoteket may be broken into a number 
of competing chains. They also implied that in future there 
should be few if any restrictions on the opening of new 
community pharmacies in Sweden.
The fact that Swedish pharmacists can, again with patient as 
well as medical permission, undertake generic substitution 
was also regarded as a significant practice development. 
Respondents were generally enthusiastic about moving 
pharmacy further in the direction of providing ‘cognitive’ 
services. However, like many pharmacists in other EU member 
states, they also expressed caution about extending the 
profession’s role into prescribing prescription only medicines, 
and taking on roles that might be seen as directly competing 
with those of doctors. One individual commented ‘it is right 
to say we are ahead in many respects, but also conservative. The 
British experiment (in pharmacist prescribing)? I think we will 
need to see how it goes before we go in that direction.’ 
A majority of respondents said that close working between 
community pharmacists and medical practitioners needs 
further to be encouraged, and that inter-professional 
communication could be improved. Swedish pharmacists are 
professionally represented by organisations such as the Swedish 
Pharmaceutical Association (Sveriges Farmacevtforbund), 
while the Swedish Academy of Pharmaceutical Sciences 
(Apotekarsocieteten) facilitates pharmacy research. 
It was argued that the existence of a strong single employer 
has helped to simplify representational processes in Sweden as 
opposed to the situation in larger and more plural countries, 
and to strengthen the professional identity of community 
pharmacists. Yet even if this is the case, the fundamental 
dilemmas and uncertainties relating to the future of pharmacy 
appear to be broadly similar across the Union.
Pharmaceutical cost controls
Sweden spends about 1.1 per cent of its GDP on hospital 
and community (OTC and prescription) medicines, costed 
at manufacturers’ (ex factory) prices (OHE 2007). Only 
countries such as Norway, the Netherlands and Denmark 
(along with Ireland, which may have data quality problems, 
and Luxembourg, which has a very high per capita GDP) 
spend less. The factors underlying this may include both 
limited volume use of many treatments and the existence of 
controls on the prices of patented and generic medicines. (A 
Dutch pharmacist interviewed informally said ‘we – northern 
European nations – all start with the Calvanist idea that using 
medicines cannot be good’.) 
With regard to new medicines the Pharmaceutical Benefits 
Board (LFN, or Lakemedelsformansnamnden) has from 2002 
determined allowable reimbursement prices on the basis of 
cost effectiveness data, and additional information such as the 
prices permitted in other EU states. Overall pharmaceutical 
costs are also limited by the use of positive and negative lists 
of prescribable products, prescriber budgets, formularies, 
generic substitution by pharmacists and prescriptionists, and 
medicine user charges. The latter involve patients paying the 
entire cost of medicines listed in the Swedish Drug Benefits 
Scheme up to the level of 900 Kroner (about £70) yearly, 
after which a graded system of support operates to a patient 
payment ceiling of 1,800 Kroner. In addition, all medicines 
licensed as OTC products must be paid for privately.
While Sweden was successful in establishing a relatively 
strong research based pharmaceutical industry in the middle 
of the twentieth century, there appears to be a belief that this 
has now been lost as a national asset as a result of mergers and 
acquisitions. Respondents expressed mixed views about such 
trends, and the international pharmaceutical industry.
Future opportunities
Sweden and the UK are geographically and socially 
very different. Sweden, for instance, has a significant 
immigrant population but lacks the large disadvantaged 
urban populations like those found throughout Britain. 
Nevertheless, their health care systems have a number of 
important similarities, and their pharmacy cultures are 
arguably more similar to each other than they are to those 
of any of the other countries considered in this report. The 
qualitative finding, therefore, that Swedish pharmacists 
interviewed appear to feel that the independent pharmacist 
prescribing of POMs is an innovation which is ahead of their 
present agenda may be taken to be significant from a pan 
European viewpoint.
With regard to developmental partnerships between 
community pharmacy and pharmaceutical companies, 
most respondents said that any new relationships should be 
established at the level of Apoteket rather than at an individual 
or local level. Some initially questioned the probity of closer 
linkages between a profession aimed at improving the public’s 
welfare and private sector organisations established to make 
profits on behalf of shareholders. There were concerns that 
inappropriate marketing might be encouraged. 
Yet on probing respondents also said that, from a rational 
perspective, productive partnerships should be possible 
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in appropriately regulated settings. It was suggested that 
key areas for possible improvement included improving 
undergraduate and postgraduate education and developing 
new approaches to the professional support of self care/
self management. It was also noted that in Sweden (as in 
Germany) OTC medicines must be paid for out-of-pocket. 
Unless new reimbursement arrangements can be made, this 
might act as an effective restraint on strategies aimed at 
extending pharmacy based care provision via enhancing the 
range of pharmacy only medicines available.
Partnerships for better care
This final section draws together the quantitative public 
opinion and qualitative professional opinion data presented 
above, and discusses its implications for pharmaceutical 
and wider health care development in Europe. It also seeks 
to identify areas in which community pharmacy and the 
research based pharmaceutical industry might, with other 
stakeholders, more effectively work together to overcome 
future challenges and improve public health. 
Relationships between pharmacy and the pharmaceutical 
industry have not always been based on an informed mutual 
understanding. One reason for this is that pharmacists are 
frequently concerned with preventing the potentially unsafe 
and/or unduly costly use of medicines. The central mission 
of research based pharmaceutical companies is, by contrast, 
to promote the potentially beneficial use of innovative 
treatments, often in uncertain clinical circumstances. 
Balancing the public’s interests in safety and expenditure 
restraint on the one hand and the development of effective 
new ways of preventing, ameliorating and curing illness 
on the other is an inherently difficult task, which requires 
maturity and good-will on all sides.
Another possible source of tension has been that pharmacy 
owners and pharmaceutical company executives may see 
themselves as being in competition in relation to the income 
to be derived from medicine sales. Recent concerns about 
how medicine supply chain reforms might not only reduce 
the risk of counterfeit products being supplied to European 
patients but also reduce costs reflect this obvious, but often 
unspoken, reality. Debate relating to such issues may also 
impinge on the need of organisations such as pharmaceutical 
wholesalers to adjust to changing circumstances. 
Some of the latter have achieved strong positions in recent years. 
In parts of Europe that have not previously permitted corporate 
ownership of community pharmacies wholesalers may now be 
well placed to extend their power by purchasing ‘independents’. 
But against this they may fear moves by pharmaceutical 
companies (which are themselves effectively prohibited from 
owning community pharmacies) to relate more directly to 
pharmacists, and cut intermediate medicines supply costs.
Complementary business models?
In the context of today’s Europe both research based 
pharmaceutical companies and community pharmacy 
need to change the business models which served them, 
and their customers, relatively well during the last half of 
the twentieth century. If they can do this via constructive 
partnership, and with a clear focus on achieving additional 
welfare for all the individuals and communities they serve, 
they will ultimately gain more than they would from conflict 
orientated approaches. The potential beneficiaries of a 
coherent, economically and functionally robust approach 
to European community pharmacy service enhancement 
include not only pharmacists, pharmacies and the enterprises 
that discover and make medicines. They ought also to include 
doctors and, most importantly, members of the public seeking 
to keep themselves and their families healthy, and/or to live 
as well as possible with ill health.
In considering issues relating to the future of pharmacy, and 
questions about whether or not current developments in 
community pharmacy in England (or other UK nations, such as 
Scotland) can reasonably be taken to indicate a general direction 
of progress for European pharmacy, distinctions need to be made 
between common (or universal) causes of health and health 
care change and special (or contingent) factors. These last may 
be locally important in particular EU member states, but are 
not significant in other parts of the Union. It is apparent, for 
instance, that the financial and social context that pharmacy 
services are provided in France is very different from that in, say, 
Poland. Examples of ‘special’ (contingent) variables include:
•	 the extent to which professional and wider communities 
have access to English language information sources. This 
(respondents said) tends to enhance awareness of wider 
international trends in pharmacy care delivery;
•	 the existence or otherwise of medical opposition to 
pharmacist role extensions, which may to a substantial 
degree be a function of medical labour under or over 
supply;
•	 following on from the above, the relative costs of medical, 
nurse and pharmacist labour;
•	 the degree to which particular member state governments 
are in conflict with their local medical profession about 
health care funding and resource allocation issues, and 
so may wish to support the development of alternative 
health care providers; 
•	 the degree to which pharmacy and other OTC medicines 
supplied via pharmacies are reimbursable, as distinct from 
having to be paid for directly out of pocket; and
•	 the extent to which dispensing related pharmacy income 
streams are threatened by local policy measures, and 
the availability or otherwise of payments for ‘cognitive’ 
service provision.
Differences in these and other local factors can make it 
difficult to see any clear Europe wide picture. Nevertheless, 
community pharmacy throughout the Union is also being 
exposed to common underlying evolutionary forces like those 
associated with the emergence of new ‘near patient’ testing 
technologies and changing public expectations of health care 
professionals and systems.
It would be inappropriate to go into undue theoretical 
detail here. But in this last context it is useful to be aware 
of models of social change that help explain general health 
care trends related to fundamental demographic, social and 
economic developments. For example, researchers such as 
Ronald Inglehart (see, for instance, Inglehart and Welzel 
2005) have published data indicating that as populations 
grow richer, more educated and more secure, individuals in 
them want not only more ‘consumer’ choice and autonomy 
in areas such as health care. People also expect more from 
governments, companies and professionals in relation to 
safety, and promoting the wellbeing of everyone within the 
(increasingly broadly defined) community. 
Hence problems such as health inequalities between social 
groups are often seen as less acceptable by people living in 
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modern consumer societies than they are in more traditional 
(perhaps superficially less materialistic) communities. 
Likewise, although medicines are arguably less hazardous 
than ever before, their unwanted side effects may be seen as 
increasingly problematic. This implies from a health sector 
management perspective that future Europeans are likely 
to want increased personal care choice and better service 
co-ordination for themselves and for others. Similarly, with 
regard to European pharmaceutical research, there are already 
rising expectations that investments in sophisticated scientific 
innovations should be accompanied by expenditures aimed at 
ensuring globally equitable access to up-to-date treatments.
Sociologists such as Richard Sennett (2006) have additionally 
observed that in advanced societies like those of western 
Europe there have been moves away from fixed, hierarchical 
and bureaucratically ordered relationships of production. The 
direction has been towards centrally led, but much less rigidly 
defined, ‘transactional’ structures. For the purposes of this 
analysis a key point to highlight is that the impact of factors 
like information technology advances is likely to lead to a 
further blurring of once firmly delineated professional roles. 
There will also be an increasing recognition of the importance 
of consumer inputs in areas such as health maintenance 
and disability management. Promoting ‘self management’ 
therefore represents a common trend in modern health care, 
which community pharmacy based health care could play a 
significant role in supporting.
In Britain the recent Wanless report’s emphasis on the 
importance of achieving greater public engagement in 
public health improvement may be taken to exemplify 
such processes (HM Treasury 2004). These trends challenge 
traditional professional attitudes and structures at all levels. 
Relevant examples can be drawn from standard setting 
and health care ‘quality management’ (a function that is 
moving away from direct professional control throughout the 
developed world) through to the formation of doctor, nurse 
and pharmacist relationships with service users. Professionals 
are being required to change the ways in which they express 
their authority and expertise. The development of the 
concepts of ‘concordance’ in relation to medicines taking 
illustrates this point.
Towards more plural health care provision 
within managed markets
Two thirds of the European general public population 
interviewed during the research undertaken for this project 
agreed with the statement ‘community pharmacies should be 
developed as alternatives to doctors’ clinics, so people have more 
choice about getting advice and treatment for common conditions’. 
When taken together with the views expressed by pharmacists 
themselves about their desired futures, this finding (which 
was robust across all age groups and both sexes) represents 
substantive evidence that European community pharmacy is 
likely to shift further in the direction of health promotion and 
health care provision (as distinct from medicines supply and 
pharmaceutical care alone) during coming decades. 
The available data indicates that there is already substantial 
public support for such a development. The reclassification 
of proven treatments for conditions like hypertension, raised 
cholesterol levels, diabetes, asthma and migraine as pharmacy 
medicines may also help facilitate such progress. Extending 
the ‘pharmacy only’ therapeutic armamentarium to in future 
include a significantly wider range of medicines would (it 
was generally agreed by pharmacist respondents) build on 
the existing reality of their direct involvement in diagnosis 
and prescribing. 
To the extent that integrated health records, whether 
held on patient smart cards or central computers, become 
available, movement in this direction could be gained 
without undermining the quality of patients’ other medical 
and nursing care. The opportunity available can be described 
as involving the development of a strengthened form of 
pharmacy supported self-care within a more co-ordinated 
framework of overall health service provision (Figure 14). 
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Figure 14. Levels of Professional and Personal Health 
Care
Through this pharmacists could further enhance the delivery 
of ‘pharmaceutical care’ (see Box 5) while increasing their 
inputs in areas such as public health improvement and the 
direct treatment of common long term and other conditions. 
This offers the prospect of greater patient choice and enhanced 
‘managed competition’, coupled with better overall service 
integration and safety protection.
The level of support for extending the existing health care 
role of pharmacists varies between European countries. It 
appears that the more the general public is satisfied with 
locally available care funding and access arrangements, 
the less there is likely to be immediate positive pressure for 
change. But it is nevertheless reasonable to conclude that 
there is a discernable European direction of progress, which 
will probably accelerate in the coming decade. Examples of 
the common (or universal) drivers for this identified during 
the course of this study include:
•	 continuing population aging and rising health and lifestyle 
expectations. Their impact will mean that primary care 
doctors and nurses will become more engaged in providing 
care for people with complex medical and support needs 
in community rather than institutional settings;
•	 government and other cost containment policies, that will 
serve to drive health (and social) care provision ‘down’ to 
lower cost, and less formal, settings;
•	 wider political recognition of the value to patients and 
the public of more managed competition in health care;
•	 the (gradual) development of computer based, consumer 
owned, health records that can be accessed by any 
authorised service provider;
Individual and family self-care
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Box 5. Pharmaceutical Care, and 
Pharmacy Based Health Care
Pharmaceutical care may be defined in a range of 
slightly differing ways. Hepler and Strand (1989) 
suggested that it encompasses ‘the responsible provision 
of drug therapy for the purpose of achieving definite 
outcomes that improve a patient’s quality of life . These 
are (i) cure of a disease; (ii) elimination or reduction of a 
patient’s symptomatology;(iii) arresting or slowing of a 
disease process; or (iv) preventing a disease or condition’. 
In essence it involves using pharmacists’ skills to 
improve the health of patients via enhancing the 
quality of medicines prescribing and use. It also 
involves individual pharmacists accepting increased 
accountability for their patients’ treatment.
It is important not to become unduly concerned with 
semantics. But the extent to which this concept can 
be extended to include the use of diagnostic and other 
clinical skills which many pharmacists may not yet 
have fully acquired is debateable. As used here the 
term pharmacy based health care includes therapeutic 
and allied services that can be offered by any clinically 
competent pharmacist or doctor, or indeed nurses with 
relevant competencies. It in addition encompasses 
offering health promotion and sickness prevention 
services, the provision of which may also go beyond 
the established definition of pharmaceutical care 
(Maguire 2007).
A number of unanswered questions exist about 
community pharmacists’ willingness to accept 
extended roles, and about how their education and 
training should and most cost effectively could be 
adapted to ensure they have the necessary capabilities. 
There are significant economic and financial barriers 
to change throughout Europe. Yet the view taken here 
is that community pharmacy will of necessity move 
more in the direction of being a direct health care 
provider, alongside being a facilitator of improved 
prescribing by other professionals and more effective 
medicines use by the public. The alternative may in the 
final analysis be redundancy, as new pharmaceutical 
supply options evolve.
the community pharmacy supply of selected prescription 
medicines in defined circumstances (like dental emergencies, 
in condition specific clinics and in out-of-hours emergency 
services provided by pharmacies) are also, on the basis of 
this research, likely to be introduced more widely across the 
European Union. 
However, the degree to which the development of free 
standing independent (as opposed to medical practice 
located) pharmacist prescribing of prescription only 
medicines will be adopted in Europe is less certain. Some 
governments may actively wish to promote this end, and 
undue conservatism should be avoided. But public opinion 
appears to be divided on its desirability. Further, pharmacists 
and their representatives often seem reluctant to support 
action that could be seen as radically altering the existing 
social concept of a prescription medicine. 
Many respondents emphasised the value of the pharmacy 
check on medical prescribing safety and appropriateness in 
relation to prescription medicine supply. This concern may 
be addressed by regulations that ensure that independent 
prescribing pharmacists do not dispense their own POM 
prescriptions. Nevertheless, the British community pharmacy 
‘experiment’ seems in this respect unlikely to provide a 
commonly followed European example within the foreseeable 
future.
Building a new dialogue between pharmacy 
and the pharmaceutical industry
Many pharmacists clearly have mixed feelings about the 
pharmaceutical industry. Some, for instance, say it is ‘too 
commercial’ (a charge often made against community 
pharmacy by other health professionals) while also saying 
that their own professional incomes should be protected. 
Others may recognise and to a degree feel dependent on 
industry’s research and financial successes, but also resent 
the strong position companies are perceived to occupy in 
society, nationally and internationally. Yet the information 
presented on pharmacists’ views and the environmental 
changes faced by both pharmacy and the pharmaceutical 
industry indicates that there is a rich agenda to be explored 
by professional and corporate leaders seeking to establish a 
constructive dialogue about the future. The analysis offered 
here indicates that opportunities for closer collaboration exist 
at three main levels:
1. Improving pharmacists’ education and skills, particularly 
in respect of their therapeutic and health behaviour 
change related competencies.
2. Specifying and establishing new pharmacy based services, 
and where appropriate complementary forms of support 
provided directly to the public by companies.
3. Changing other health sector stakeholders’ knowledge 
and attitudes, and influencing national and regional 
policies in ways consistent with the public’s interests in 
better pharmaceutical and pharmacy based care.
A range of relevant themes that the qualitative research 
on which this report is based has highlighted are outlined 
below. Most have the potential to be translated into practical 
activities that could be undertaken at all three of these 
levels.
•	 the further establishment of the ‘medical breakthroughs’ 
of the second half of the twentieth century as safe and 
affordable therapies suitable for pharmacy sale;
•	 the availability of new dispensing technologies and 
services; and
•	 the development of new forms of risk factor and diagnostic 
testing suitable for pharmacy and/or end point consumer 
use, alongside the concentration of much modern 
medicines research on highly sophisticated, high unit cost, 
therapies. The latter will be most likely to be of value to 
relatively small numbers of people in receipt of hospital 
care.
These last points suggest that the income streams available to 
community pharmacies from drug supply alone will almost 
certainly decline, although this should be compensated 
for by new opportunities for providing clinical and linked 
health behaviour change services. Seen from this perspective, 
initiatives like measures in the UK aimed at the establishment 
of community pharmacies as ‘public health outposts’ have 
a general European salience. Protocol based approaches to 
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Medicines licensing, and achieving more shifts towards 
pharmacy supply
Changing medicines’ classifications will not in itself create 
a health care environment in which pharmacists can play a 
significantly extended role. Yet moving more medicines to 
pharmacy only supply status will probably be a necessary 
element in the twenty first century development of pharmacy 
based health services. Such reclassifications should primarily 
reflect the development of robust data on the safety of 
products in normal use, rather than being led by factors such 
as patent expiry dates alone. 
Similarly, where there is a strong public health improvement 
based case for moving selected medicines on further to a 
free sale basis, sectional professional or commercial interests 
should not seek to block such developments. However, where 
there is no clear public interest case favouring making a given 
type of medicine available anywhere, there is a robust case in 
favour of its retaining pharmacy status.
Looking at medicines licensing more widely, there may also 
be public benefits to be gained from stronger pharmacy 
and pharmaceutical industry inputs into policy debate on 
issues such as how an optimal balance between preserving 
safety and facilitating prompt access to new treatments can 
best be achieved. Ensuring the economically viable and 
clinically appropriate ‘conditional’ availability of innovative 
therapies for life threatening conditions such as cancer is 
another potentially important topic for pharmacists and 
pharmaceutical companies to consider together.
Ensuring appropriate pharmacist access to computerised 
health care records
Many respondents agreed that if pharmacy based health care 
is to be made more widely available in ways that maximise 
additional benefits, pharmacists must be in a position to not 
only see but also contribute to patients’ full care records. 
In all the national settings examined, respondents were 
aware of at least some developments relating computerised 
health care and/or medication records. But in overall terms 
current progress falls far short of the ideal of establishing 
fully comprehensive, integrated, systems consistently 
available to pharmacists. Here again there are many potential 
opportunities for collaborative working at local, national and 
European levels, aimed at making optimal use of existing 
resources and promoting new investments.
Joint initiatives in this area could also involve extending 
electronic prescribing in ways that optimise the use of existing 
pharmacy resources, and ensure that patient choices are fully 
respected in relation to where and how medicines are supplied 
and who is empowered to see and change health records. In 
this last context aspects of Swedish personal care practices and 
service values appear worthy of particularly close attention. 
Arguably it should be service users rather than providers who 
have ultimate authority over health record access. 
Maintaining positive and constructive relationships with 
the medical profession
The expansion of health care and allied service provisions 
via community pharmacies is sometimes, misleadingly or 
otherwise, presented as a threat to the medical profession. To 
the degree that patients and individuals seeking to maintain 
good health could enjoy more choices, limited competition 
will inevitably result. But in a changing world this should not 
be taken to mean that doctors will be made superfluous, or 
that their legitimate authority will be undermined. 
Rather, in systems based on an ethos of professional co-
operation alongside the pursuit of greater service efficiency, 
appropriate consumer sovereignty and better use of 
community pharmacy resources should help to manage 
medical workloads to better effect. It should also serve to 
maintain and improve the quality of doctors’ prescribing 
and patients’ medicine taking, rather than to undermine 
the strength of their relationships. However, this end will 
probably prove unachievable if most members of the medical 
profession do not see it as desirable and acceptable. This study 
offers robust evidence that throughout Europe more could 
and should be done to improve the working relationships 
between community pharmacists and doctors.
German insurance company schemes that promote the use 
of general practitioners and financially incentivise doctors 
and community pharmacists to work together may offer 
an example that it could in future usefully explored within 
the NHS, and other Union health care systems. There are 
important opportunities for pharmacists and pharmaceutical 
companies to work with members of the medical profession 
to build confidence and mutual understanding, and support 
further the implementation of policies that would underpin 
productive joint working.
The aim of such activity should at all levels be to create shared 
visions of ‘pharmaceutical care’, and greater expectations of 
community pharmacists and primary care doctors working 
together. This will not only promote better outcomes for those 
using their services but also offer secure environments for 
the professionals concerned. All the countries reviewed here 
have with varying levels of success sought to establish general 
medical practice based access routes to specialist/hospital care 
in recent decades. One important goal of collaborative work 
in this area could be to demonstrate how in Europe extending 
pharmacy based health services would enable general medical 
practice further to develop.
The financing of public access to prescription and OTC 
medicines
Countries such as France, Greece, Sweden and Germany 
have differing systems for funding and facilitating public 
access to medicines. Variations in these structures have led 
to marked variations in patterns of pharmacy only as well as 
prescription medicine use. The French overall ‘OTC’ market 
is consequently the largest in Europe. The Swedish market is, 
in both absolute and relative terms, significantly smaller. If 
the future development of European pharmacy health care 
is, as is suggested here, likely to in part involve increases in 
the use of pharmacy only medicines, more appropriate public 
and/or private systems for reimbursing their immediate out-
of-pocket cost may well need to be established. They should 
logically be aimed at preventing income related inequalities 
in pharmacy care access, and discouraging its misuse.
This (together with the parallel challenge of seeking further 
to harmonise European approaches to charging patients for 
prescription items obtained via publicly funded care) therefore 
represents another possible area for collaboration between 
pharmaceutical companies and pharmacy as a public interest 
orientated profession. Work in fields like the establishment of 
new pharmaceutical care insurance schemes might also address 
problems arising from situations in which ‘cost effectiveness 
regulators’ such as NICE in the UK, or The Institute for Quality 
and Efficiency in Health Care in Germany, advise against the 
use of medicines that a proportion of service users have reason 
to believe will benefit them.
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Protecting public interests in the ownership and location of 
community pharmacies
In France, Germany and Sweden pharmacy ownership 
structures have been challenged by European authorities 
seeking to ensure appropriate competition. This has created 
considerable concern. Pharmaceutical companies have no 
direct interest in this area, save to serve all their customers 
as well as they can. Yet given the vital importance of 
community pharmacy in the medicines supply chain and 
the use of medicines, this does not mean to say that the 
pharmaceutical industry and the pharmaceutical profession 
should not at a policy level together seek to assure European 
public interests in good quality, comprehensively available, 
pharmacy services.
Establishing robust evidence based approaches to the 
regulation of community pharmacy numbers and locations 
is one topic that might benefit from a careful joint analysis. 
A related area that might usefully be explored in partnership 
is the possible future application of competition law in 
ensuring that in coming decades community pharmacy does 
not become inappropriately concentrated. Europeans should 
wherever possible be able to access a true choice of pharmacy 
service provider types. 
Policy on medicines parallel trading with the Union
Some observers assume that the present system of medicines 
parallel trading between European member states benefits 
community pharmacy and health care funders, at no 
significant cost to the public. However, the true picture is more 
complex, as the evidence presented here from countries such 
as Greece and Poland suggests. (See also Taylor and Campling, 
2006.) The pursuit of a single European market, with the free 
movement of goods and services across all internal borders, 
on occasions conflicts with the legitimate pursuit of both 
national and European level interests in safety and access to 
medicines on the one hand, and research and innovation 
on the other. Pharmaceutical companies and pharmacists 
have a legitimate mutual interest in understanding this area 
robustly, and – if informed agreements can be established 
– working together constructively to shape policy in the 
overall European public’s interests.
Ensuring medicines supply chain integrity
The survey results in this report show that three quarters of 
the European citizens interviewed believe there is a growing 
risk from counterfeit medicines in Europe. This perceived risk 
is lower in France and the UK than it is in Germany, Greece 
and Sweden. But public confidence in medicines supply 
chain security is clearly under significant threat throughout 
the Union. This problem has a potential to impact on the 
reputations of all those involved in providing medicines. 
Given mutual good-will and respect, pharmacy’s professional 
representatives and research based pharmaceutical companies 
should be able to develop and implement shared approaches 
to more effectively guaranteeing the supply of genuine 
medicines. They need to develop strategies that are 
demonstrably cost effective from a governmental perspective, 
as well as financially viable from the standpoint of private 
sector stakeholders in the European medicine supply 
chain.
Extending pharmacists’ clinical competencies, and 
developing new community pharmacy service models
Contributors to this research were largely agreed that 
community pharmacy needs enhanced skills in areas such 
as communication with patients, and the delivery of care 
for common – rather than merely minor – conditions. One 
example noted on several occasions is that of the identification 
and treatment of raised blood pressure. Much has already 
been achieved, with clearly beneficial consequences in 
areas such as heart attack and stroke death rate reductions. 
Many effective anti-hypertensive medicines are not only 
of well proven relative safety, but also now available at low 
cost. However, much more could be done – even in western 
Europe – to optimise the benefits of existing pharmaceutical 
treatments (Kanavos 2007). 
Similar cases might be made not only in contexts such as 
lowering cholesterol levels, but also with regard to examples 
such as the delivery of services like contraceptive and sexual 
health care, immunisations, and the treatment of diabetes 
and associated states. Pharmacy support for smoking cessation 
can be regarded as providing a starting point for a much 
wider range of interventions aimed at stimulating health 
behaviour change, and the effective use of medicines. Yet a 
French respondent argued strongly that although extending 
relevant forms of pharmacy based health care has a significant 
potential to reach sections of the population that are not 
adequately served by existing provisions, adequate efforts 
are not being made by pharmacists themselves to foster new 
services. It is similarly estimated that in the US only about 10 
per cent of pharmacists are actively committed to extending 
pharmaceutical care (Strand 2007).
Survey participants were also largely agreed – despite the 
caveats entered by some about ‘profit seeking’ motives 
– that pharmaceutical companies are well placed to support 
the further development of community pharmacy skills 
and services. Realistic strategies must of course be found to 
generate the income needed to fund pharmacy based ‘disease 
management’ interventions. But consciousness of this should 
not undermine awareness of the important potential for joint 
working aimed at relevant educational, service and policy 
developments.
Informing the public about common health problems, and 
the ways they can most effectively be avoided and treated
The ICM survey results reported earlier consistently pointed to 
high (sixty five per cent plus) levels of European public support 
for policies that would permit pharmaceutical companies to 
communicate information directly to patients and potential 
medicine users through suitably regulated websites. This 
finding appears to challenge current EU regulations, and 
the views sometimes expressed by individuals seeking to 
champion health care consumer interests. Information on US 
company websites is already, of course, available to Europeans 
who are able to speak English and can access a computer.
Ethical community pharmacists wish to ensure that their 
customers receive accurate guidance, and are not misled. 
Some of those interviewed also seemed to be worried that 
if members of the public could obtain information about 
medicines from sources other than themselves, the position 
of pharmacy as a profession might be weakened. However, 
such sectional concerns do not offer a sound basis for policy. 
A further area for collaboration between the representatives 
of pharmaceutical companies and pharmacy is therefore that 
of enhancing public access to medicines related information, 
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and increasing awareness of the circumstances in which 
accessing diagnostic and allied testing and preventive, 
ameliorative and curative treatments in pharmacy and other 
settings can bring genuine benefits. 
Defining, funding and leading pharmaceutical care
As Box 5 (page 32) discusses, term such as ‘pharmaceutical 
care’ can have a range of meanings. Just as in the past 
pharmaceutical companies and the pharmacy profession 
have collaborated to develop concepts such as ‘concordance’, 
so might they in future work together further to clarify and 
enhance public, professional and political understanding of 
pharmaceutical care and the provision of pharmacy based 
health care. It is arguably important that public expectations 
of the latter should be raised, to allow primary care systems 
to evolve.
Joint initiatives relating to this objective could also help 
further to strengthen pharmacy leadership across Europe, 
which has long been recognised as a critically important 
factor. At the start of the 1990s Professor Sir Michael Rawlins 
(who was subsequently to become chairman of NICE) wrote 
with respect to pharmacy in Great Britain ‘that there is an 
extended role for the community pharmacist is accepted by the 
government and many other bodies…… The profession’s leaders 
have a considerable responsibility, however, in ensuring that the 
potential is fulfilled’ (Rawlins 1991). The same can be said today 
throughout Europe.
Funding medicines research for the future – patents, brands 
and the proper place of minimal cost generics
The funding of pharmaceutical research via market based 
financial mechanisms, as opposed to tax payer contributions, 
depends critically on the existence of mechanisms for 
protecting intellectual (IP) and trade property. Without these, 
no private individual or corporation investing in research of 
any kind can be assured of making appropriate returns. 
Patenting and branding have occupied an especially important 
place in the pharmaceutical sector. Once discovered and 
developed medicines are often relatively easy to copy. To the 
extent that public investment – outside areas such as defence 
– is for the most part made only when there is a reasonable 
prospect of success leading to financial returns on world 
markets, it can be argued that the existence of IP protection is 
also vital for the maintenance of tax based research funding. 
Hence measures that effectively weaken IP protection for 
medicines in Europe threaten the future financial viability 
of not only research based pharmaceutical companies, but 
also the academic, health service and other institutions they 
directly and indirectly fund. (See, for instance, Action Research 
and Community Health India et al 2006.) 
Modern pharmacy is often concerned with limiting or 
reducing drug costs. Nevertheless, as a profession, pharmacy 
also retains a special stake in medicines innovation, and 
the continuing improvement of treatments for patients. 
Seen from this perspective there are potentially important 
opportunities for the European and global profession to work 
with the pharmaceutical industry to promote better public 
understanding of not only science, but also of economic issues 
appertaining to science.
Facilitating equitable global access to effective medicines 
As noted at the start of this section, there is evidence that 
citizens of societies such as those of the European Union 
are becoming increasingly unwilling to accept that people 
anywhere in the world should be deprived of effective health 
care. While the commercial funding of pharmaceutical 
innovation is for a number of reasons becoming more 
problematic, there are rising demands that as soon as new 
treatments are licensed they should become globally available, 
to poor people as well as the rich.
The history of anti-HIV medicines discovery and supply 
illustrates this point, and the fact that pharmaceutical 
companies rather than governments may be blamed if less 
advantaged populations cannot get access to treatments. 
There is also some international questioning relating to the 
role pharmacy as a profession should play in improving 
global access to medicines, not just in capital city centres but 
also in less accessible poor urban and rural areas. It can be 
argued that alongside developing their interest in maintaining 
the financial viability of pharmaceutical research for the 
future, pharmacy ought also to work more closely with 
pharmaceutical companies to develop better approaches to 
facilitating equitable global access to effective medicines.
Conclusion
There is good reason to say that there is currently more 
opportunity for community pharmacy to extend its 
contributions to health and wellbeing of Europeans than at 
any time in the past century. The factors underpinning this 
reality include not only technical advances and changing 
health care needs. There are public expectations for a greater 
role for pharmacy across much of the Union. In countries 
such as the UK there is additionally informed medical backing 
for the strengthening of community pharmacists’ skills, and 
the part they can play in maintaining and improving health 
outcomes (Fradd 2007). 
The EU can already claim to be the world’s healthiest 
major region. If developed rationally and effectively, its 
comprehensive community pharmacy network will contribute 
significantly to achieving further reductions in morbidity and 
mortality in the coming century.
However, against this positive background there remain major 
challenges to be overcome. Some of the most important exist 
within community pharmacy itself. Professor Linda Strand 
originated, with Professor Doug Heppler, the concept of 
pharmaceutical care at the start of the 1990s. She recently 
commented (at a conference held to encourage Polish 
pharmacy reform) that in many instances ‘the pharmacist is 
the rate limiting step’ (to the achievement of pharmacy progress 
- Strand 2007). Her remarks reflect those made by other 
observers about issues such as defensiveness, pharmacists’ 
seeming aversion to risk, and the extent to which their daily 
workload of high volume dispensing prevents members of the 
profession from taking their activities into new dimensions. 
Strand and others have called for more investment in 
developing clinical skills, and putting individual and public 
health improvement at the heart of pharmacy’s professional 
identity. It may also be suggested that pharmacy’s commercial 
incentives to supply medicines, rather than medicines related 
health care, will need to change. 
This may be true, at least in as much as any group’s financial 
incentives should ideally be aligned with its highest priority 
36 Greater Expectations
goals. But it is also important to stress that part of the unique 
value of community pharmacy is its capacity to treat people 
as customers rather than patients. 
From a public interest perspective care should be taken not 
to lose this advantage as the role of pharmacists in Europe’s 
communities adapts to not only support prescription medicine 
selection and taking more effectively, but also to facilitate 
informed self care and directly provide more established 
treatments for common conditions. Rather than thinking of 
this as a form of ‘re-professionalisation’, pharmacists would 
perhaps be better advised to see themselves as embarking on 
a course which will in time lead to the ‘re-normalisation’ of 
many aspects of the types of health care they are uniquely 
placed to provide in the community.
The evidence gathered in this study indicates that across 
Europe the funding base underpinning past patterns of 
community pharmacy activity is already changing. In the 
reimbursed prescription medicines sector it is becoming more 
transparent, and separated from the prices of medicines that 
are given to patients. Over time new methods of medicines 
dispensing, coupled with better access to health records, will 
also help pharmacy to develop further its place in health care 
delivery alongside that of nursing and medicine. 
Related forces are driving the research based pharmaceutical 
industry to revise the business model which enabled it 
successfully to develop and supply new medicines during 
the second half of the twentieth century. In this sense, both 
pharmacy and the pharmaceutical industry face an uncertain 
yet potentially highly productive future. 
It remains to be seen whether or not they will be able to 
work together effectively to realise their shared opportunities. 
But in the final analysis, medicines makers and medicines 
suppliers do not exist in a vacuum. The task facing pharmacy 
and the pharmaceutical industry extends well beyond re-
engineering their bilateral relationship, or even building 
further their working partnerships with doctors and nurses. 
It involves understanding with greater empathy the values, 
aspirations and overall (health) economies of the communities 
they exist to serve, and finding ways of meeting the needs 
of people in them which are progressively more relevant 
and respected. This involves building greater expectations 
of pharmacy, and pharmaceutical innovations. If European 
community pharmacy can promote this end it will in time 
gain a new level of security for itself, and the society of which 
it will become an even more integral part.
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